Entries |
Document | Title | Date |
20080248102 | Rapidly Dissolving Pharmaceutical Compositions Comprising Pullulan - The present invention provides an orally dissolving capsule comprising pullulan, a plasticizer and a dissolution enhancing agent. | 10-09-2008 |
20080260814 | INJECTION MOULDING PROCESS FOR NEUTRAL AND ACID-GROUP-CONTAINING (METH)ACRYLATE COPOLYMERS - Processes for producing moldings by injection moulding, include melting a mixture made from a (meth)acrylate copolymer and a release agent, devolatilizing the mixture, injecting the molten and devolatilized mixture into a mold cavity of an injection mold, cooling the molten mixture, and removing the resultant molding from the mold. | 10-23-2008 |
20080268037 | Autonomous method for oral delivery of a healing substance to a target place in gastrointestinal tract of humans or animals - A method for oral delivery of new drugs, big molecules, proteins, and healing substances to a target place in the body, via digestive tract, using mobile self-controlled capsules with sensors. | 10-30-2008 |
20080268038 | Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength - Provided are compositions and methods for increasing diet induced thermogenesis. Typically, the compositions are comprised of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-valine and L-threonine. | 10-30-2008 |
20080274174 | STABLE PANCREATIC ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. | 11-06-2008 |
20080292692 | Impermeable Capsules - A capsule comprising a core and a shell surrounding and enclosing the core, the shell comprising at least one first polymer having a first water solubility parameter, and at least one second polymer having a water solubility parameter higher than the first water solubility parameter, wherein the second polymer is crosslinked, and/or all of the at least one second polymer is present in an amount that is less than all of the at least one first polymer. Upon exposure to an aqueous medium, the first polymer begins to swell, and water begins to leak into the capsule. Also, the second polymer is attracted to the entering water. As the second polymer absorbs water and swells, the mean free space in the shell decreases and the tortuous pathway for materials crossing the boundary of the wall increases. As a result, leakage rates across the capsule wall decrease. | 11-27-2008 |
20080299187 | Substances for Reducing Occurence of Major Cardiac Events in Humans - A medicament comprising a dispersion of Red Yeast Rice extract in Omega-3 Oils. The medicament is supplied in capsules such that a daily dose is dispensed in an integral number of capsules. A dispersant is used, preferably Lysine and bamboo. The ratio of Red Yeast Rice Extract to EPA+DHA is in the range between about 1.4 and 2.8. The medicament reduces cholesterol, triglycerides, and reduces serious heart incidents. | 12-04-2008 |
20080311187 | CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substances (A) from the dosage form is at least partially delayed. | 12-18-2008 |
20080311188 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A SIP RECEPTOR AGONIST AND A SUGAR ALCOHOL - A solid pharmaceutical composition suitable for oral administration, comprising:
| 12-18-2008 |
20090011009 | Microspheres comprising nanocapsules containing a lipophilic drug - The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical compositions comprising the same as well as methods of use of the microspheres, specifically, in therapeutic, cosmetic and diagnostic applications. | 01-08-2009 |
20090017111 | TOLTERODINE BEAD - A controlled release tolterodine bead is formed having a microcrystalline cellulose core, a PVP-containing water soluble coating, a tolterodine drug layer, and a controlled release layer. | 01-15-2009 |
20090028935 | CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF - Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions. | 01-29-2009 |
20090035367 | CONTROLLED DEGRADATION OF EXPANDABLE POLYMERS IN GASTRIC VOLUME REDUCTION TREATMENT - Orally administrable polymer-carrying units for expanding in a stomach of a mammal to fill a space in the stomach, the polymer-carrying units including: a carrier; a plurality of polymer molecules expandable in aqueous solutions, releasably coupled to the carrier; and means for selectively decoupling the polymer molecules from the carrier so that the polymer molecules and carrier are released in the stomach, are provided. | 02-05-2009 |
20090035368 | EMBEDDED MICELLAR NANOPARTICLES - The present invention relates to a thermostable solid composition containing nanosized micelles, the micelles containing a poorly soluble chemical substance, such as a biologically active substance, dissolved in an auxiliary material, and the micelles being embedded in a water soluble carrier. The invention further relates to a process for preparing a thermostable solid composition and to a process for preparing pharmaceutical dosage forms comprising the same. | 02-05-2009 |
20090041838 | Anti-Misuse Microparticulate Oral Drug Form - The invention relates to solid microparticulate oral dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient (API) contained therein. The aim of the invention is to prevent the improper use of solid oral drugs for any use other than the therapeutic use(s) officially approved by the appropriate public health authorities. Another aim of the invention is to provide novel analgesic drugs which can be used to: prevent the misuse of, and addiction to certain analgesics and/or to control plasma concentration variability and/or to facilitate oral; administration; and/or to combine analgesics with one another and/or with one or more active ingredients in the same oral form. More specifically, the invention relates to a solid oral drug form comprising anti-misuse means and at least one active ingredient, which is characterized in that: at least part of the active ingredient is contained in microparticles; and the anti-misuse means comprise anti-crushing means (a) which enable the microparticles of the active ingredient to resist crushing, such as to prevent the misuse thereof. According to the invention, the drug form can also comprise means (b) for preventing the misuse of the active ingredient following a possible liquid extraction process. | 02-12-2009 |
20090041839 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN - The present invention provides pharmaceutical compositions comprising an allosteric adenosine A | 02-12-2009 |
20090060993 | SOLID PHARMACEUTICAL COMPOSITION FOR ENHANCED DELIVERY OF COENZYME Q-10 AND UBIQUINONES - The present invention describes a solid oral dosage form of ubiquinones (e.g., ubidecarenone, coenzyme Q-10, idebenone or mixture thereof), providing on contact with water or body fluids the regulated release of an “in situ” formed oil-in-water emulsion with ubiquinone incorporated in the oil phase. Described formulation demonstrates improved bioavailability. | 03-05-2009 |
20090081286 | Extended release venlafaxine formulation - A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet. | 03-26-2009 |
20090087484 | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules - A formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules includes a permeation enhancer, a hydrophilic macromolecule, and a carrier such as a nonionic surfactant that exhibits in-situ gelling properties. The formulation is delivered within the GI tract as a liquid having at least some affinity for the surface of the GI mucosal membrane. Once released, it is believed that the liquid formulation spreads across one or more areas of the surface of the GI mucosal membrane, where the carrier of the formulation then transitions into a bioadhesive gel in-situ. As a bioadhesive gel, the formulation presents the hydrophilic macromolecule and the permeation enhancer at the surface of the GI mucosal membrane at concentrations sufficient to increase absorption of the hydrophilic macromolecule through the GI mucosal membrane over a period of time. A dosage form incorporates the formulation and may be designed to provide the controlled release of the formulation within the GI tract over a desired period of time. | 04-02-2009 |
20090098200 | COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION - Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media. | 04-16-2009 |
20090110722 | Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 04-30-2009 |
20090130197 | EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT - An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient. | 05-21-2009 |
20090155354 | DISPENSING ENCAPSULATED LIQUIDS INTO BODY CAVITIES - Body tissue or cavities are treated by inserting a membrane module containing a substance for treating a condition of the cavity or tissue. The substance is enclosed in a membrane that melts, dissolves, or dissipates in the environment of the cavity such as a vagina to release the substance into the cavity. | 06-18-2009 |
20090162429 | Slow-Release Composition, Method for the Preparation Thereof, and Use Thereof - The pharmaceutical or nutraceutical composition with sustained release of an active ingredient according to the present invention comprises at least one coated granule; the coated granule being composed of a particle that comprises said active ingredient and is coated with at least two coatings that comprise a combination of excipients. The present invention relates also to a process for the preparation of the composition. | 06-25-2009 |
20090191265 | Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients - A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need. | 07-30-2009 |
20090196919 | OXCARBAZEPINE DOSAGE FORMS - The present invention relates to dosage forms of oxcarbazepine for oral administration that contain oxcarbazepine having a median particle size of from about 14 μm to about 30 μm and to processes for the preparation of such dosage forms. The dosage form may be a solid or a liquid dosage form. The solid dosage form may be in the form of a tablet, a capsule, or a granulate. The liquid dosage form may be in the form of a solution or a suspension. | 08-06-2009 |
20090208568 | Gellan Seamless Breakable Capsule and Process for Manufacturing Thereof - The invention relates to a process for manufacturing a seamless breakable capsule, comprising—co-extruding an external and hydrophilic liquid phase, and an internal and lipophilic liquid phase, in order to form a capsule constituted of a core comprising the internal and lipophilic phase, and a shell comprising the external and hydrophilic phase,—immersing into an aqueous solution containing a curing agent, wherein the external liquid phase includes a gelling agent comprising gellan gum alone or in combination with another gelling agent, a filler, and a divalent metal sequestering agent, and to breakable capsules comprising a core and a shell, wherein the shell includes a gelling agent comprising gellan gum alone or in combination with another gelling agent, a filler, and a divalent metal sequestering agent. | 08-20-2009 |
20090214640 | DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MAKING SAME - The present invention relates to a delayed release pharmaceutical oral dosage form and method of making same. The delayed release dosage form comprises one or more active ingredients within a granulated composition, which further comprises one or more excipients selected from the group of solid aliphatic alcohols, fatty acid esters, mixtures of esters of saturated fatty alcohols and saturated fatty acids, natural waxes, synthetic waxes, hydrogenated castor oil, hydrogenated vegetable oil, gums, and mixtures thereof; and one or more polymers or copolymers exhibiting a pH-dependent solubility. The present invention also related to method of making these delayed release dosage form. | 08-27-2009 |
20090220590 | Triple drug combinations for psychiatric patients - The mega capsule can be prescribed by any physician, and in particular those professionals in the psychiatric field. The mega capsule will be a form of medication designed for a specific patient in mind. The capsule will help the patients understand their medications better and make it easier for them to take. The patient may only have to take the mega capsule once or twice a day and by doing that, the patient will feel more in control of their prescriptions. By inventing the mega capsule, we may lower the cost significantly for the patients. Altogether, it will make life easier for the patients and the physicians. | 09-03-2009 |
20090252787 | GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient. | 10-08-2009 |
20090258065 | Dermatological compositions comprising avermectin nanocapsules - Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea. | 10-15-2009 |
20090263476 | Composition of Rapid Disintegrating Direct Compression Buccal Tablet - A composition of a rapidly disintegrating buccal dosage form containing a drug, at least one non-effervescent base such as an alkali metal or alkaline earth metal oxide or hydroxide, and a disintegrant. The base regulates the pH gradient to deliver the drug to the buccal, sublingual or oral mucosal membranes at a desired rate of absorption. The composition is micronized for uniform distribution, and the drug is converted from ionized form to unionized form, without the use of an effervescent agent. | 10-22-2009 |
20090263477 | SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF - In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. | 10-22-2009 |
20090269398 | Compositions for the encapsulation of natural product extracts in oil medium in hard gelatin capsules and a method of encapsulation - The present invention relates to compositions of natural extracts in oil medium, prepared in non-free-flowing formulations, and encapsuled in hard gelatin capsules, without post-fill sealing. These compositions comprise a therapeutically effective amount of at least one natural extract in oil medium, the composition suitable for treating a medical condition, and at least one oil-absorbent ingredient in powder form. More specifically, the natural extract in the composition can be an extract of | 10-29-2009 |
20090269399 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF - The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts. | 10-29-2009 |
20090304786 | Stable Dosage Forms of an Antidepressant - The present invention relates to stable solid dosage forms of an antidepressant. More particularly, the present invention relates to stable solid dosage forms of bupropion hydrochloride. The present invention also relates to a process for the preparation of stable solid dosage forms of bupropion hydrochloride. | 12-10-2009 |
20090304787 | DRUG DELIVERY COMPOSITION - A drug delivery composition that comprises extruded spheroids. The spheroids comprise at least one active pharmaceutical ingredient; at least one extrusion-spheronization aid; at least one superdisintegrant; and at least one glidant, at least one lubricant, and/or at least one oil. The spheroids may also be coated. In a further aspect, a drug delivery composition that comprises coated spheroids that have inert spheroids and at least one coating for the spheroids. The coating comprises at least one active pharmaceutical ingredient and at least one superdisintegrant. | 12-10-2009 |
20100015220 | NIACIN AND NSAID COMBINATION THERAPY - Provided are pharmaceutical compositions and methods for preventing or reducing niacin-induced flushing comprising an aspirin component and a niacin component having different release profiles. Also provided are methods and compositions for preventing or reducing niacin-induced flushing comprising niacin, aspirin and a lipid-lowering drug other than niacin. | 01-21-2010 |
20100021536 | ENHANCED-DIFFUSION CAPSULE - An ingestible capsule is provided for delivering medication to a subject. A capsule coating dissolves in a gastrointestinal tract of the subject. An inner core of the capsule has an outer surface associated therewith. The outer surface is disposed within the coating and expands when the coating dissolves. A medication is disposed on the outer surface, and the outer surface is configured such that the medication contacts an intestinal wall of the subject when the outer surface expands. Other embodiments are also provided. | 01-28-2010 |
20100055173 | RELEASE OF STATINS IN THE INTESTINE - The present invention provides a controlled absorption formulation in which modified release of the active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than that can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, a subcoat surrounding the core comprising at least one water soluble hydrophilic carrier and an outer coating. The core is optionally and preferably in the form of a tablet. | 03-04-2010 |
20100055174 | CHEWABLE SOFTGEL CAPSULES - A chewable softgel capsule configured for encasing orally ingestible articles. The chewable soft capsule is provided with an outer shell composition which comprises at least one gelatin in a range of 20% to 60% of the total weight of the shell composition, at least one plasticizer in an amount selected to render flexible the outer shell composition, an anti-tacking agent in an amount selected to render the outer shell composition non-sticky, and water. In one embodiment the chewable soft capsule further comprises at least one starch in a range of 0.1% to 35% of the total weight of the shell composition. The chewable softgel capsule is suitable for encasing therein medicines, pharmaceutical compositions, nutraceuticals, vitamins, nutritional supplements, and the like. | 03-04-2010 |
20100074947 | Pharmaceutical Formulations - The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form. | 03-25-2010 |
20100080846 | DIPYRIDAMOLE AND ACETYLSALICYLIC ACID FORMULATIONS AND PROCESS FOR PREPARING SAME - The present invention provides pharmaceutical formulations of dipyridamole and acetylsalicylic acid, methods of making thereof, and methods of using thereof. | 04-01-2010 |
20100092548 | CHEWABLE SOFTGEL CAPSULES - A chewable softgel capsule configured for encasing orally ingestible articles. The chewable soft capsule is provided with an outer shell composition which comprises at least one gelatin in a range of 20% to 60% of the total weight of the shell composition, at least one plasticizer in an amount selected to render flexible the outer shell composition, an anti-tacking agent in an amount selected to render the outer shell composition non-sticky, and water. In one embodiment the chewable soft capsule further comprises at least one starch in a range of 0.1% to 35% of the total weight of the shell composition. The chewable softgel capsule is suitable for encasing therein medicines, pharmaceutical compositions, nutraceuticals, vitamins, nutritional supplements, and the like. | 04-15-2010 |
20100104634 | PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE - The invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. | 04-29-2010 |
20100112045 | SURFACE-TREATED MODAFINIL PARTICLES - The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof. | 05-06-2010 |
20100112046 | FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME - The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution. | 05-06-2010 |
20100129442 | Oral Multi-Functional Pharmaceutical Capsule Preparations Of Proton Pump Inhibitors - An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate; a population of a basic substance; and a second population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a second rate. In another embodiment, the oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a population of a pharmaceutical active; a population of a basic substance; a population of enteric coated pharmaceutical active; and a population of enteric coated basic substance. The composition can provide multiple site specific delivery of a pharmaceutical active in a rapid, delayed and/or sustained release manner into the plasma. | 05-27-2010 |
20100136104 | NUTRITIONAL SUPPLEMENT FOR USE UNDER PHYSIOLOGICALLY STRESSFUL CONDITIONS - In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 300 mg of vitamin C; about 1200 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folate; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 300 mcg of biotin; about 50 mg of calcium; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 25 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 2 mg of lutein; about 500 mcg of lycopene; about 5 mg of pepper extract; and at least one or more excipients. | 06-03-2010 |
20100143459 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR - A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. | 06-10-2010 |
20100143460 | SOLID DOSAGE FORMS COMPRISING ALISKIREN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention relates to a pharmaceutical formulation comprising aliskiren or a pharmaceutically acceptable salt thereof as the active ingredient, wherein the pharmaceutical formulation is present in a solid dosage form suitable for oral administration based on a granulate obtained by a hot-melt and solvent-free granulation process, and to a process for manufacturing a pharmaceutical formulation. | 06-10-2010 |
20100143461 | PALONOSETRON FORMULATION - The present invention provides solid oral formulations of palonosetron or salts thereof. | 06-10-2010 |
20100151010 | MEDICAMENT IN A MULTILAYER FORM - The invention relates to a medicament in a multilayer form, containing a) a core with a pharmaceutical agent, b) an inner coating, 50 to 95 percent by weight of which arc composed of a (co)polymer comprising 95 to 100 percent by weight of radically polymerized vinylic monomers with neutral side groups and 0 to 5 percent by weight of monomers with anionic side groups, c) an outer coaling made of a copolymer comprising 75 to 95 percent by weight of radically polymerized C | 06-17-2010 |
20100151011 | SOLID ORALLY ADMINISTERABLE PHARMACEUTICAL DOSAGE FORMS WITH RAPID ACTIVE PRINCIPLE RELEASE - The present invention relates to solid pharmaceutical dosage forms which can be administered orally and comprise 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide in amorphous form and/or thermodynamically metastable crystal modification and have rapid release of active ingredient, and to process for the production thereof, the use thereof as medicament, the use thereof for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and to the use thereof for producing a medicament for the prophylaxis, secondary prophylaxis and/or treatment of disorders. | 06-17-2010 |
20100151012 | STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALINE - Solid pharmaceutical composition containing: (a) pregabaline as active principle and (b) one or several pharmaceutical auxiliary agents, the composition being essentially free from saccharides and comprising no further amino acids, apart from pregabaline. | 06-17-2010 |
20100151013 | Gastric acid secretion inhibiting composition - An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid. | 06-17-2010 |
20100158997 | BLOW-MOLDED THIN-WALLED DRUG DELIVERY CAPSULES - A thin-walled capsule of defined permeability is produced by blow-molding an aqueous-based polymer composition. | 06-24-2010 |
20100158998 | FORMULATIONS COMPRISING VITAMIN D OR DERIVATIVES THEREOF - The present invention provides stable formulations of vitamin D or a derivative thereof, preferably cholecalciferol. | 06-24-2010 |
20100178333 | SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER - Once a day sustained release solid oral dosage form of phenothiazine derivative preferably the dibenzothiazepine derivative and their pharmaceutically acceptable salts comprising of a channelizer, rate controlling polymer and suitable pharmaceutically acceptable excipients. The formulation of the present invention is in the form of tablet or capsule which provides a sustained drug action upto 24 hours upon single dose administration. | 07-15-2010 |
20100178334 | Oral Pharmaceutical Dosage Form Comprising as Active Ingredients a Proton Pump Inhibitor together with Acetyl Salicyclic Acid - The present invention relates to an oral pharmaceutical preparation for use in the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid. The present preparation comprises a fixed oral dosage form comprising a proton pump inhibitor in combination with acetyl salicylic acid. Furthermore, the present invention refers to a method for the manufacture thereof and the use thereof in medicine. The present invention also relates to a specific combination comprising esomeprazole, or an alkaline salt thereof or a hydrated form of any one of them, and acetyl salicylic acid for use as a medicament for the prevention of thromboembolic vascular events, such as myocardial infarction or stroke, and for the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid. | 07-15-2010 |
20100178335 | Formulations of acetylsalicylic acid or its derivatives in soft capsules, exhibiting high stability - The present invention relates to new formulations comprising acetylsalicylic acid or its derivatives an oil phase and a cyclodextria in soft capsules, characterized by a high stability. | 07-15-2010 |
20100178336 | STABILIZED AMORPHOUS FORMS OF IMATINIB MESYLATE - The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N--[4-methyl-3-( 4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions. | 07-15-2010 |
20100183709 | FORMULATION - The present invention relates to therapeutic formulations based on pumpkin products, in particular to encapsulated formulations for oral administration. A product of the invention comprises a hard gelatin capsule which encloses a unit dose of a formulation which comprises at least 50% by weight of one or more pumpkin product. | 07-22-2010 |
20100196465 | STABLE PHARMACEUTICAL COMPOSITION OF A WATER-SOLUBLE VINORELBINE SALT - A stable pharmaceutical composition comprising a water-soluble vinorelbine salt and at least one diluent and one lubricant, characterized in that it appears in a solid form intended for oral administration. The water-soluble vinorelbine salt is advantageously vinorelbine ditartrate. The pharmaceutical composition advantageously appears as a gelatin capsule or tablet. | 08-05-2010 |
20100196466 | DRUG DELIVERY SYSTEM - A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided. | 08-05-2010 |
20100203120 | PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS - An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. | 08-12-2010 |
20100209495 | GRANULATES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL PRODUCTS CONTAINING THEM - A granulate for use in a pharmaceutical composition and a pharmaceutical composition manufacture using the granulate, where the granule comprises an active pharmaceutical ingredient (API) having a poor water solubility (i.e., less than about 1 mg/mL) which is intimately associated with at least one pharmaceutically acceptable hydrophilic polymer. The granule optionally contains one or more pharmaceutically acceptable excipients, such as disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The invention also relates to a process for preparing the pharmaceutical granulate and pharmaceutical compositions containing the granulate. | 08-19-2010 |
20100215735 | Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the Compounds - Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells. | 08-26-2010 |
20100221323 | Crystal Entecavir Formulation And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection, comprising the crystal entecavir as pharmaceutically active ingredients and pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have more stronger stabilization than that of amorphous entecavir under conditions of lighting, high temperature and high humidity. | 09-02-2010 |
20100239661 | PHARMACEUTICAL COMPOSITIONS OF URSODIOL - A pharmaceutical composition is disclosed. The composition comprises a therapeutically effective amount of active pharmaceutical ingredient that is Ursodiol or its pharmaceutically acceptable salts thereof with one or more pharmaceutically acceptable excipients, wherein said active pharmaceutical ingredient present in the form of micronized and unmicronized particles in the ratio about 5:95 to about 95:5. | 09-23-2010 |
20100239662 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. The second layer, which can be adjacent the first layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles in the first layer. The composition further comprises a superabsorbent material (for example, polycarbophil) disposed within the first layer, the second layer, or both the first layer and the second layer. When intact, the pharmaceutically active agent is released from the second layer faster than the pharmaceutically active agent in the first layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition. Also disclosed is a method of using the misuse preventative, controlled release composition to deliver at least one pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 09-23-2010 |
20100255083 | CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION AND PROCESS FOR ITS PREPARATION - The present invention relates to a controlled-release pharmaceutical formulation comprising at least one active ingredient dispersed in a matrix comprising at least one slow-release excipient comprising an association of at least one glycogen and at least one alginate with alkaline-earth metal salts, and a process for its preparation. The invention also relates to a slow-release excipient comprising an association of at least one glycogen and at least one alginate with alkaline-earth metal salts, and the process for its preparation, and its use for the preparation of slow-release pharmaceutical formulations. | 10-07-2010 |
20100255084 | Medicinal melting capsules for oral mucosal absorption - A medicinal melting capsule comprised of a material that has the same melting point as the human body temperature and includes a therapeutic amount of medication for use in treatment of a desired medical condition; wherein the medication has been modified for oral mucosal absorption; and a related method for delivering medication to an individual via oral mucosal absorption comprising the steps of providing a melting capsule comprised of a material, that has the same melting point as the human body temperature, and includes a therapeutic amount of medication for use in treatment of a desired medical condition; modifying said medication by manipulating the solvent, pH, buffer material and/or polarity to adjust for oral mucosal absorption; administering the capsule sublingually in the patient such that the capsule melts at the individual's body temperature and delivers the medication directly into the bloodstream of the individual quickly and without gastric complications. | 10-07-2010 |
20100272792 | STABILITY ADDITIVES FOR DRY DHA DOSAGE FORMS - The use of additives to stabilize DHA when compressed into tablets, or filled as a powder into capsules, for oral administration. | 10-28-2010 |
20100278908 | COMPOSITIONS INCORPORATING AGENTS FOR REDUCING CELLULITE AND UNAESTHETIC APPEARANCE ASSOCIATED THEREWITH AND FORMULATIONS CONTAINING THEM - The present invention relates to synergic compositions incorporating agents for reducing cellulite and unaesthetic appearance associated therewith which comprise a base matrix constituted by conjugated linoleic acid (CLA), grape seed extract, beta-glucan, organic calcium and dry extract of pine bark together with complementary synergic agents of the matrix. The invention also relates to the use of such compositions and formulations containing said compositions. | 11-04-2010 |
20100278909 | PROCESS FOR FORMING SOLID ORAL DOSAGE FORMS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS - A method for producing granules of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, which comprises: a) mixing the angiotensin II receptor antagonist or pharmaceutically acceptable salt thereof with a melt granulating agent to form a mixture; b) elevating the temperature of the mixture to the melting point of the melt granulating agent to form a solid dispersion of the angiotensin II receptor antagonist in the melt granulating agent; and c) cooling the solid dispersion to form granules; wherein the melt granulating agent is the only granulating agent used to form the granules. | 11-04-2010 |
20100285115 | Novel Antiretroviral Combination - The invention relates to pharmaceutical compositions containing a combination of atazanavir and ritonavir, to methods of making them, and their use in medicine. | 11-11-2010 |
20100291199 | Compositions and Methods For The Treatment and Prevention of Disease - The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof. | 11-18-2010 |
20100297220 | Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders - Pharmaceutical formulations in the form of a powder for suspension comprising at least one proton pump inhibitor in micronized form; at least one antacid; and at lest one suspending agents are provided herein. Also provided herein are methods for making and using pharmaceutical formulations comprising at least one proton pump inhibitor and at least one antacid. | 11-25-2010 |
20100310650 | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation - A pharmaceutical composition for the oral administration of omega polyenoic fatty acids combined with one or more active principles incompatible therewith, is described; also described is a process for preparing said pharmaceutical composition. | 12-09-2010 |
20100323005 | Sodium Ibuprofen Tablets and Methods of Manufacturing Pharmaceutical Compositions Including Sodium Ibuprofen - Sodium ibuprofen compositions and methods of manufacturing tablets and caplets comprising sodium ibuprofen are described. The formulation is advantageous because it allows for the formation of tablets having low sodium content and further provides tablets exhibiting improved physical stability, high tablet hardness and high strength, coupled with excellent dissolution and bioavailability characteristics. The formulations and processes are further advantageous because they can be produced in large quantities without an unacceptable number of defective tablets. | 12-23-2010 |
20100330169 | Pharmaceutical Tablet Containing A Liquid Filled Capsule - In one aspect, the present invention features a tablet including a compressed core and a liquid filled capsule, wherein the compressed core includes a first pharmaceutically active agent, the compressed core has a cavity exposed on the surface of the core, and the capsule is contained within the cavity such that a portion of the capsule is visible on the surface of the tablet, wherein the capsule has a diameter of at least 500 microns. | 12-30-2010 |
20100330170 | Flavored Vegetarian Cellulose Capsule and Methods for Producing said Capsule - A flavored vegetable starch capsule and the method of manufacture of the flavored capsule is provided. The capsule may comprise (a) from about 95% to about 100% parts by weight of cellulose, such as hydroxymethylcellulose; (b) from about 0.5% to about 5.5% by weight of a suitable hydrogenated saccharide, such as sorbitol; (c) from about 0.2 to about 2.5% of a lubricant, such as silicon dioxide; (d) up to about 10% purified water; to which is added about 1/10 parts by weight of liquid flavoring. | 12-30-2010 |
20110008423 | PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULES OF PURIFIED MICROBIAL LIPASE AND METHODS FOR PREVENTING OR TREATING DIGESTIVE DISORDERS - The present invention relates to pharmaceutical compositions comprising granules containing at least one recombinantly produced purified microbial lipase, the use of said pharmaceutical compositions for the manufacture of a medicament for the prevention or treatment of certain diseases or disorders like pancreatic endocrine insufficiency, and a process for the manufacture of said pharmaceutical compositions. | 01-13-2011 |
20110008424 | Sustained Release Solid Formulations and Methods of Manufacturing the Same - Disclosed are a sustained release solid formulation comprising a drug, for example, oxycodone or its pharmaceutically acceptable salt, in a water-insoluble matrix, which comprises a wax type excipient and copovidone, and thus, has increased compressibility and fluidity and reduced adhesiveness, and a method of preparing the same. | 01-13-2011 |
20110014280 | SEQUESTERING SUBUNIT AND RELATED COMPOSITIONS AND METHODS - A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent. | 01-20-2011 |
20110014281 | DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES - This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substance, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system. The invention also relates to a method for controlling the particle size and/or particle shape and/or particle size distribution in such a drug delivery system, and to a method for increasing the drug loading capacity of the particles. Furthermore the invention also relates to the use of such a drug delivery system for the preparation of a medicament for the treatment of cancer. | 01-20-2011 |
20110014282 | PHARMACEUTICAL COMPOSITION FOR POORLY SOLUBLE DRUGS - A pharmaceutical composition containing a solid dispersion of a poorly soluble active pharmaceutical ingredient, an amorphous carrier and a surfactant. | 01-20-2011 |
20110020438 | Crystallization Inhibitor and Its Use in Gelatin Capsules - The present invention describes soft gelatin capsules that encapsulate a water-insoluble active ingredient and an excipient composed of a crystallization inhibitor that stabilizes the water-insoluble inhibitor. The crystallization inhibitor being at least one mononacylglycerol compound whose acyl group is a fatty acid residue of 6-18 carbon atoms. The capsule contents are more resistant to turbidity, forming a coarse emulsion, and crystallization of the active ingredient compared with compositions absent the crystallization inhibitor. | 01-27-2011 |
20110020439 | DELAYED RELEASE COMPOSITIONS OF DULOXETINE - A delayed release dosage form comprising core comprising duloxetine or its pharmaceutically acceptable salts or derivatives thereof, optionally, other pharmaceutically acceptable excipient(s) thereof; intermediate layer; and enteric layer; wherein the dosage form comprises one/more dissolution enhancer(s), wherein the enteric layer comprises one/more enteric polymers other than hydroxypropylmethyl acetate succinate. A process of preparing a delayed release dosage comprising mixing pharmaceutically acceptable excipients with duloxetine or its pharmaceutically acceptable derivatives thereof; granulating the product of previous step compressing the granulate formed in previous step to form core, coating said core with intermediate layer followed by coating with one/more enteric polymers and optional finishing coating. A delayed release dosage form comprising: core comprising duloxetine or its pharmaceutically acceptable derivative thereof, intermediate layer and enteric layer comprising one/more enteric polymers other than hydroxypropylmethyl acetate succinate; wherein dosage form contains one/more dissolution enhancer(s) and has improved dissolution. | 01-27-2011 |
20110045064 | FORMULATIONS OF 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease. | 02-24-2011 |
20110045065 | SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to medicinal formulations having anti-oxidant, geroprotective and anti-ischemic activity. Said formulations include 3-hydroxy 2,4,6 trimethylpyridine, pharmaceutically acceptable salts, esters, derivatives and polymorphs thereof. | 02-24-2011 |
20110059166 | HIGH STRENGTH SEAMLESS ALGINATE CAPSULES - The invention is directed to a seamless alginate capsule having a film encapsulating a fill material, in which the film comprises alginate, noncrystallizing plasticizer, and glycerol and in which a ratio by weight of noncrystallizing plasticizer to glycerol in the film is between about 1:1 and about 8:1. The invention is also directed to a method of making the seamless alginate capsules and to capsules made by the method. The capsules have excellent breaking strength and are resistant to oxidation of the fill material. | 03-10-2011 |
20110064799 | Pancreatic Enzyme Compositions and Methods for Treating Pancreatitis and Pancreatic Insufficiency - Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies. | 03-17-2011 |
20110064800 | NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CYCLOSPORINE - The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. | 03-17-2011 |
20110064801 | Pharmaceutical Formulations Containing an SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 03-17-2011 |
20110070299 | DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF DULOXETINE - A pharmaceutical composition comprising duloxetine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient(s) characterised in that the duloxetine has a D | 03-24-2011 |
20110070300 | EXTENDED RELEASE DOSAGE FORMS OF METOPROLOL - The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms. | 03-24-2011 |
20110081413 | Pharmaceutical Compositions Comprising Phosphate-Binding Polymer - The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and/or added monovalent anion source. | 04-07-2011 |
20110091537 | Anti-misuse solid oral pharmaceutical form provided with a specific modified release profile - The present invention relates to a solid oral pharmaceutical form, with modified release of at least one active ingredient, containing at least microparticles containing said active ingredient and at least one viscosifying agent in a form isolated from said microparticles of active ingredient, characterized in that said microparticles possess an average diameter ranging from 100 to 600 μm, and are formed by a core containing at least said active ingredient and coated with at least one coating layer,
| 04-21-2011 |
20110091538 | POLYMER ADAPTED TO RELEASE BIOACTIVE AGENTS IN VIVO, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARATION THEREOF - The present invention provides a Monodisperse Polymer Particles (MPP) adapted to release alkoxy groups by means of a hydrolyser, such that Monodisperse Bioactive Polymer Particles (MBPP) are obtained in vivo. The MBPP are characterized by (a) at least one naturally occurring or synthetic long molecular chain consisting of biologically stable backbones optionally crosslinked, further characterized by a molecular weight of at least 1 KD, comprising between 10 to 1,000,000 repeated covalently-linked small molecules with a functionality of at least one alkoxy releasing group per molecule; (b) a long dimension between 0.1 and 10 micrometers; and, (c) a zeta potential value of 30 to 130 mV at pH of about 7.0. The MBPP alter, inhibit, activate, induce or otherwise affect biological or chemical events in vivo. | 04-21-2011 |
20110097396 | PEELING CAPSULE WITH INTEGRATED CARE EFFECT - A cosmetic capsule which can be topically applied and rubbed in and comprises a casing material and a filling material enclosed by the casing material. The casing material is composed of an emulsion which comprises one or more waxes that are solid above 25° C. and the filling material comprising a preparation which has an abrasive effect and comprises one or more abrasive peeling agents which are present in an oil or lipid mixture, a surfactant-containing preparation or an emulsion. | 04-28-2011 |
20110104267 | Pharmaceutical compositions of antiretrovirals - The present invention relates to the stable pharmaceutical dosage forms of combination of antiretroviral agents. More particularly, the present invention relates to stable pharmaceutical dosage forms of Lamivudine, Zidovudine and Nevirapine, prepared by granulation technology. | 05-05-2011 |
20110104268 | GALENIC APPLICATIONS OF SELF-EMULSIFYING MIXTURES OF LIPIDIC EXCIPIENTS - A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps. | 05-05-2011 |
20110111018 | COATED TABLET FORMULATIONS AND USES THEREOF - The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets. | 05-12-2011 |
20110111019 | Novel Method for Producing Nanocapsules in the Absence of an Organic Solvent, and Nanocapsules Produced Thereby - The invention relates to a method for preparing an aqueous suspension of nanocapsules comprising an oily core surrounded by a polymeric shell, in which method the following phases are mixed:
| 05-12-2011 |
20110117190 | Pharmaceutical Formulations - The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form. | 05-19-2011 |
20110123606 | ORAL COMPOSITION CONTAINING AN ANTIPLATELET AGENT OF THE THIENOPYRIDINE FAMILY IN THE FORM OF FREE BASE - The invention relates to non hemolytic compositions containing an antiplatelet agent such as clopidogrel or ticlopidine; these compositions being characterized in that the antiplatelet agent is in the form of free base, and the composition contains at least one hydrophilic non ionic surfactant. The invention relates also a galenic form, a method of preparation of thereof, as well as therapeutic uses of thereof, especially in patients who suffer from undesirable effects related to hemolysis and/or gastrointestinal acidity. | 05-26-2011 |
20110123607 | DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF A WATER SOLUBLE, CATIONIC AND AMPHIPHILIC PHARMACEUTICALLY ACTIVE SUBSTANCE - A drug delivery system (DDS) for administration of a water soluble, cationic, and amphiphilic pharmaceutically active substance (API) which DDS comprises poorly water soluble nanoparticles formed by the API together with a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester. A pharmaceutical composition comprising such a DDS. Methods for preparation of such a DDS and such a pharmaceutical composition. Use of such a DDS and pharmaceutical composition for treatment of cancer. | 05-26-2011 |
20110123608 | PHARMACEUTICAL FORMULATION - The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form. | 05-26-2011 |
20110123609 | MULTIPLE UNIT DOSAGE FORM OF NIACIN - A multiple unit dosage form useful for treating or preventing hyperlipidemia and/or atherosclerosis, wherein multiple unit dosage form comprise of a therapeutically effective amount of niacin or its derivatives and one or more control releasing agent(s) and pharmaceutically acceptable excipients, weight percentages are based upon the total weight of the dosage form. The multiple unit dosage form may comprise of optionally other antihyperlipidemic agent, more preferably HMG CoA reductase inhibitor. The most preferable dosage form is capsule. Further a kit comprising one or more capsules co-packaged to provide multiple unit dosage form of niacin or its derivatives in combination with HMG CoA reductase inhibitor is disclosed. | 05-26-2011 |
20110142926 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery. | 06-16-2011 |
20110159083 | Nanoparticles for protein drug delivery - The invention discloses nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge. The bioactive agent is hydrophobic or lipophilic in nature and is associated with micelles before being encapsulated in nanoparticles. | 06-30-2011 |
20110159084 | RALOXIFENE PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising raloxifene or its salts, esters, polymorphs, isomers, hydrates, solvates, or derivatives thereof having defined particle sizes. Also described are processes for preparing formulations and methods of using such formulations. | 06-30-2011 |
20110159085 | ABT-263 CAPSULE - A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 06-30-2011 |
20110159086 | PHARMACEUTICAL FORMULATION COMPRISING A CB1-RECEPTOR COMPOUND IN A SOLID SOLUTION AND/OR SOLID DISPERSION - The present invention relates to a pharmaceutical formulation comprising 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as racemate or (S)-enantiomer or mixtures thereof in a solid solution and/or solid dispersion. | 06-30-2011 |
20110159087 | Crosslinked Polymers - Disclosed herein are pharmaceutical compositions comprising wet granulated bile acid sequestrants having the general Formula I shown, and their process of preparation. The present invention also discloses process for preparation of Colesevelam hydrochloride, an antilipemic agent. | 06-30-2011 |
20110171295 | IMMEDIATE RELEASE COMPOSITIONS OF ACID LABILE DRUGS - The present invention provides a method of creating a macro environment in the stomach for immediate release of acid labile compounds stable at alkaline or near alkaline pH comprising the step of administering a composition comprising acid labile compound stable at alkaline or near alkaline pH together with a water soluble buffer, a water insoluble buffer, a disintegrant and pharmaceutically acceptable excipients. The present invention also provides a pharmaceutical composition of a multi component system in which one component essentially contains an acid labile drug and the other component comprises a fast releasing buffer composition along with pharmaceutically acceptable excipients for oral administration and ingestion by a subject, and process for preparing the same. | 07-14-2011 |
20110171296 | METHOD AND PREPARATION FOR BINDING ACETALDEHYDE IN SALIVA, THE STOMACH AND THE LARGE INTESTINE - The object of the invention is the use of compounds comprising one or more free sulphhydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds. | 07-14-2011 |
20110171297 | SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE - The invention provides a sustained release composition that; (1). Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or totally coated by a functional coating layer or film. (2). Delivers the drug substance within 24 hours and is therefore suitable for once daily administration of the said drug substance. (3). Exhibits linearity between the strength dosage form and the (total mass of the dosage form, by proportional increase of the amounts of the drug substance and the excipients in the formulation. (4). Is possible to be divided in smaller doses, without affecting the release of the drug substance. The invention provides a sustained release capsule formulation containing an appropriate number of functional complex mini tablets comprising of: (1). A functional core comprising the active ingredient, especially the water-soluble drug Venlafaxine HCl and appropriate excipients. (2). A functional coating layer or film that reduces the initial surface of the core that is available for the release of the water-soluble drug Venlafaxine HCl phenomenon. | 07-14-2011 |
20110182985 | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof - The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide. | 07-28-2011 |
20110195117 | CONTROLLED RELEASE COMPOSITIONS OF ROPINIROLE - A novel oral controlled release pharmaceutical composition comprising a therapeutically effective amount of active substance, ropinirole or a pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) or hydrate(s) thereof, one or more controlled release agent(s), optionally one or more pharmaceutically acceptable excipient(s) and an extended release coating, wherein the said composition provides controlled release of the active agent with reduced initial burst release. | 08-11-2011 |
20110206761 | STABLE DOSAGE FORMS OF ANTIHYPERTENSIVE AGENTS - The technical field of the present invention relates to stable solid dosage form comprising combination of antihypertensive agents. More particularly, the present invention relates to stable solid dosage form comprising combination of angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB). | 08-25-2011 |
20110206762 | ORAL PHARMACEUTICAL FORMULATION OF PELUBIPROFEN WITH IMPROVED DISSOLUTION RATE AND STABILITY - Disclosed is an oral pharmaceutical formulation of pelubiprofen which is improved in dissolution rate and stability. As a result of an improvement in the dissolution rate of pelubiprofen, the oral pharmaceutical formulation can show high bioavailability and thus exert pharmacological effects thereof rapidly. It also can be stored with high stability as a result of the minimal generation of related compounds. | 08-25-2011 |
20110217369 | FENOFIBRATE COMPOSITIONS - The present invention relates to a fenofibrate composition comprising: fenofibrate, a surfactant, a hydrophilic polymer and one or more anti-foaming agents. The invention also relates to a novel process for preparing said composition that has enhanced dissolution and absorption characteristics. | 09-08-2011 |
20110223244 | ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS - Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof. | 09-15-2011 |
20110223245 | CONTROLLED-RELEASE FORMULATIONS OF PRAMIPEXOLE - A controlled-release pharmaceutical formulation, comprising pramipexole or a pharmaceutically acceptable salt of pramipexole, colloidal silicone dioxide, and glyceryl behenate. | 09-15-2011 |
20110229561 | Extended Release Pharmaceutical Composition Of Entacapone Or Salts Thereof - There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions. | 09-22-2011 |
20110236474 | Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration - The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above. | 09-29-2011 |
20110236475 | GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient. | 09-29-2011 |
20110244034 | SUSTAINED RELEASE DRUG DELIVERY SYSTEM - The invention discloses a controlled release dosage form comprising a therapeutically effective amount of a pharmaceutically active agent, illustrated by Acyclovir, that would release in about 12 hours not more than about 90% of the said active agent in a simulated gastric juice in a first order rate of release in a USP type 1 dissolution test, and not containing a solubilizer or a swelling enhancer or both, comprising (a) a tablet made from polymer matrix of at least two biocompatible polymers, illustrated by Carbopol 974P and polyethylene oxide, the said pharmaceutically active agent and pharmaceutically permitted excipients; the said tablet capable of rapid swelling without disintegration in the said simulated gastric juice to a size that shall result in its gastric retention in the stomach and start controlled release of the said active agent by starting controlled erosion as well as diffusion immediately after coming into contact with the said gastric juice, or (b) microspheres of ungrafted chitosan or a chitosan derivative illustrated by thiolated chitosan and trimethyl chitosan, or Carbopol incorporating the said active agent, wherein the said pharmaceutically active agent is not a polymeric molecule and after administration in stomach, the said microspheres adhare to the gastric mucosa for a long time releasing the active agent in a controlled way. | 10-06-2011 |
20110250268 | Compositions and Methods for Inhibiting Gastric Acid Secretion - The present invention is related to novel oral compositions comprising an irreversible gastric H | 10-13-2011 |
20110256217 | PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL DRUG ABSORPTION - Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a penetration enhancer which are released at a first location in the intestine, and a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix. This penetration enhancer is released at a second location in the intestine downstream from the first location and enhances absorption of the drug when it reaches the second location. | 10-20-2011 |
20110262532 | Controlled Release Hydrocodone Formulations - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 10-27-2011 |
20110262533 | PHARMACEUTICAL FORMULATION FOR USE IN HIV THERAPY - The invention discloses a formulation prepared by granulating at least one anti-retro viral drug and at least one pharmaceutically acceptable additive, using an organic solvent; milling the product; finally processing the milled product to form tablets or capsules. | 10-27-2011 |
20110268792 | SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS - The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e.g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host. | 11-03-2011 |
20110280936 | Self Breaking Tablets - Self-breaking tablet and capsule formulations with a similar in vitro drug release profile for whole tablet and when broken and/or a bioequivalent drug release profile when taken whole or when broken are provided. Methods for production of these formulations and tablets and their administration are also provided. | 11-17-2011 |
20110280937 | HARD CAPSULE - The object of the invention is to provide a hard capsule that is excellent in stability even when filled with a solvent for dissolving a poorly soluble pharmaceutical active ingredient, and that has excellent mechanical strength in a low-humidity environment. The invention provides a hard capsule having a film containing (A) a polymer or copolymer obtained by polymerizing or copolymerizing at least one polymerizable vinyl monomer represented by Formula (1): H | 11-17-2011 |
20110280938 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION OF QUETIAPINE AND PROCESS FOR PREPARATION THEREOF - The present invention relates to sustained release pharmaceutical composition of quetiapine, and process for preparing such composition. More particularly, it relates to sustained release pharmaceutical composition of quetiapine comprising a non gelling agents such as carrageenan and pharmaceutically acceptable excipients. | 11-17-2011 |
20110287092 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF - Compositions comprising decitabine and tetrahydrouridine for the treatment of blood disorders and hematological and solid malignancies are described. | 11-24-2011 |
20110300209 | MODIFIED RELEASE SOLID PHARMACEUTICAL COMPOSITIONS OF TRIMETAZIDINE AND PROCESS THEREOF - There is provided a modified release solid pharmaceutical composition comprising Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant. | 12-08-2011 |
20120003305 | Oral Dosage Forms Of Bendamustine - In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide. | 01-05-2012 |
20120003306 | Pharmaceutical composition of nanoparticles for protein drug delivery - The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery. | 01-05-2012 |
20120021051 | ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM - A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects. | 01-26-2012 |
20120027851 | METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 02-02-2012 |
20120027852 | PHARMACEUTICAL COMPOSITION CONTAINING A "LIMUS" FAMILY IMMUNOSUPPRESSIVE MACROLIDE - A pharmaceutical formulation includes a Limus family immunosuppressive macrolide on a pharmaceutically acceptable excipient, which may be compounded as suitable for oral administration. | 02-02-2012 |
20120045506 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EMPLOYING A COATING COMPRISING NEUTRAL VINYL POLYMERS AND EXCIPIENTS - The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.1 to 30% by weight of a plasticizer whereby the excipients of the excipients portion b) are each calculated on the dry weight of the polymer portion a). | 02-23-2012 |
20120064153 | Compositions and Methods for Treating Centrally Mediated Nausea and Vomiting - Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery. | 03-15-2012 |
20120064154 | SOLID DRUG FOR ORAL USE - The present invention provides a solid oral dosage form pharmaceutical for the treatment of dysuria, which comprises, as an active ingredient, an indoline compound having an α | 03-15-2012 |
20120076855 | Oral testosterone composition - The composition for oral administration of testosterone to a man who has androgen deficiency and exhibits one or more symptoms of androgen deficiency, comprises testosterone and a mixture of soybean oil and ethanol. | 03-29-2012 |
20120082719 | Compositions For Treating Chronic Viral Infections - The present invention describes dietary compositions and methods of using such compositions to treat chronic viral infections, including hepatitis B and hepatitis C infections. | 04-05-2012 |
20120107395 | Probiotic Soft Gel Compositions - Soft gel capsules are formed from an outer gelatin-containing shell and a filling. The filling includes a probiotic and a dessicant. | 05-03-2012 |
20120114750 | PHARMACEUTICAL COMPOSITION 271 - The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions. | 05-10-2012 |
20120121700 | PHARMACEUTICAL FORMULATIONS COMPRISING VALGANCICLOVIR - Pharmaceutical formulations prepared by granulating valganciclovir or a salt thereof, using a nonaqueous solvent or hydro-alcohol. | 05-17-2012 |
20120121701 | PHARMACEUTICAL COMPOSITION OF PEPTIDE DRUG AND ENZYME-INHIBITION COMPOUNDS - The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject. | 05-17-2012 |
20120128767 | THERAPEUTIC CALCIUM PHOSPHATE PARTICLES AND METHODS OF MAKING AND USING SAME - The present invention provides novel calcium phosphate nanoparticles suitable for efficient encapsulation of biologically active molecules. The invention further provides pharmaceutical compositions comprising these nanoparticles, as well as methods of making such nanoparticles and using them as carriers for therapeutic delivery of biologically active macromolecules. | 05-24-2012 |
20120128768 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY - The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. | 05-24-2012 |
20120141580 | CAPSULE FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism. | 06-07-2012 |
20120141581 | CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism. | 06-07-2012 |
20120141582 | Thixotropic Oil Based Vehicle for Pharmaceutical Compositions - The present invention relates to a novel thixotropic oily vehicle comprising between about 0.2% to about 5% (w/w) of a colloidal silica and between about 0.2% to about 5% (w/w) of a hydrophilic polymer in an edible oil. The interaction between the hydrophylic polymer and the colloidal silica in the above concentration ranges confers thixotropy and a low viscosity under shear on the solution. The invention also relates to capsules filled with the above thixotropic solution used as a fill mass. | 06-07-2012 |
20120156286 | COMPOSITIONS AND METHODS FOR INCREASED DELIVERY OF COENZYME Q10 - Disclosed are compositions comprising Coenzyme Q10 and a cetylated fatty acid blend, pharmaceutical formulations comprising the same and methods of increasing the systemic concentration of Coenzyme Q10 in an individual, comprising administering the same to the individual. | 06-21-2012 |
20120156287 | Use of Vitelline Protein B as a Microencapsulating Additive - The present invention includes compositions and methods for the use of an encapsulation additive having between about 0.1 to about 30 percent isolated and purified vitelline protein B to provide for mixed and extended release formulations. | 06-21-2012 |
20120164216 | PHARMACEUTICAL COMPOSITION OF DULOXETINE OR PHARMACEUTICALLY - The invention relates to a taste masked pharmaceutical composition comprising duloxetine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. The invention further discloses an inclusion complex comprising duloxetine or pharmaceutically acceptable salts thereof with one or more cyclodextrin or derivatives thereof. | 06-28-2012 |
20120164217 | SCENTED CAPSULES - The present invention relates to new scented hard capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration to humans or animals of products such as pharmaceuticals or cosmetics. | 06-28-2012 |
20120171284 | CELECOXIB COMPOSITIONS - Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders. | 07-05-2012 |
20120177730 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 07-12-2012 |
20120177731 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 07-12-2012 |
20120183607 | STABLE DOSAGE FORMS OF SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS - The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w. | 07-19-2012 |
20120189692 | Pharmaceutical Compositions of Iron for Oral Administration - The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders. | 07-26-2012 |
20120201876 | METHOD OF MANAGING HYPERCORTISOLEMIA, HEADACHE DISORDERS, NEUROPATHIC PAIN AND RELATED DISORDERS - The present disclosure relates to treatment and management of Cushing's syndrome, Headache disorders and Neuropathic using a composition comprising asiaticoside and madecasosside optionally along with at least one excipient. The treatment can be extended to Myalgia and other related disease conditions. | 08-09-2012 |
20120207824 | ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 08-16-2012 |
20120207825 | PHARMACEUTICAL COMPOSITIONS FOR REDUCING ALCOHOL-INDUCED DOSE DUMPING - A pharmaceutical composition is disclosed. The composition comprises a core comprising an active substance or a salt thereof; a separating layer comprising at least one sugar; and a functional layer comprising at least one pharmaceutically acceptable polymer, wherein the composition is resistant to dose dumping in presence of alcohol. | 08-16-2012 |
20120225118 | COMPOSITIONS FOR DELIVERY OF INSOLUBLE AGENTS - Compositions and methods of making the same for improving the bioavailability of a substantially water-insoluble pharmacologically active agent are described. The composition includes a substantially water-insoluble pharmacologically active agent, and a substantially water-insoluble matrix forming material comprising enzyme digestible or bile soluble nutrients, wherein the substantially water-insoluble pharmacologically active agent is dispersed in a solid matrix and wherein said pharmacologically active agent in said matrix is substantially free of the original crystalline form. | 09-06-2012 |
20120244215 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C | 09-27-2012 |
20120244216 | COATED PHARMACEUTICAL CAPSULE DOSAGE FORM - Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient. | 09-27-2012 |
20120244217 | 4-METHYLPYRAZOLE FORMULATIONS - Provided herein are 4-methylpyrazole (4-MP) formulations, stable under storage conditions of up to about 55° C. | 09-27-2012 |
20120258167 | ORAL PHARMACEUTICAL COMPOSITION - The present application provides a method for treating or preventing Celiac disease. In one embodiment the method comprises administering to a patient in need thereof a composition comprising minicapsules, wherein the minicapsules comprise a steroid in a liquid, semi-solid or solid core, the minicapsules having release profiles to release the steroid in an active form at one or more sites along the gastrointestinal tract, the one or more sites comprising the proximal small intestine beginning at the duodenum and ending at the ileum. In a related embodiment the method comprises administering budesonide to a patient in need thereof in a pre-solubilised drug delivery format. | 10-11-2012 |
20120263786 | Pharmaceutical Formulations Containing an SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 10-18-2012 |
20120269890 | PROCESS FOR OBTAINING A ROSUVASTATIN CALCIUM COMPOSITION AND OBTAINED PRODUCT - The present invention describes a rosuvastatin calcium composition that does not require tribasic phosphate salts to be stable and that also has suitable bioavailability, and is helpful in reducing lipid and/or cholesterol levels in the body, as well as the manufacturing method of this composition. | 10-25-2012 |
20120276196 | Pharmaceutical Compositions of a Neuroactive Steroid and Methods of Use Thereof - The present invention relates to pharmaceutical compositions of the neuroactive steroid 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, with properties desirable for use in treating mood disorders and the like. The pharmaceutical compositions provide sustained therapeutic plasma levels of 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one. The present invention also relates to methods of treating these disorders by administering the pharmaceutical compositions. | 11-01-2012 |
20120282332 | COMPOSITION AND METHOD THEREOF - The present disclosure relates to a composition comprising Trigoneoside Ib and Vicenin-1 for treatment and management of Goodpasture's disease, Glomerulonephritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Idiopathic Thrombocytopenia Purpura. The present disclosure also relates to a method of obtaining the said composition from | 11-08-2012 |
20120282333 | DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF MESALAMINE - The invention relates to a delayed release pharmaceutical composition of mesalamine comprising: a) granules comprising mesalamine or pharmaceutically acceptable salts thereof and a hydrophilic polymer; b) extragranular excipients; wherein the pharmaceutical composition is further coated with a single layer of polymer. | 11-08-2012 |
20120294936 | REDUCED MASS METFORMIN FORMULATIONS - The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules. | 11-22-2012 |
20120294937 | NEW PHARMACEUTICAL DOSAGE FORM FOR THE TREATMENT OF GASTRIC ACID-RELATED DISORDERS - According to the invention there is provided a capsule for peroral administration to the gastrointestinal tract containing (a) a pharmacologically effective amount of a PPI or a pharmaceutically acceptable salt thereof and an enteric substance positioned to protect the PPI or salt thereof from the acidic environment of the stomach, and (b) a plurality of granules comprising a pharmacologically effective amount of a micronised H2RA or a pharmaceutically acceptable salt thereof, a disintegrant and a filler The capsules of the invention are particularly useful in the treatment of gastric acid secretion-related disorders, such as gastro-esophageal reflux disease. | 11-22-2012 |
20120294938 | PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION - Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described. | 11-22-2012 |
20120301541 | COMPRESSED CORE FOR PHARMACEUTICAL COMPOSITION - A compressed core for a pharmaceutical dosage form comprising a mixture of (a) at least one pharmaceutically acceptable organic acid, and (b) at least one pharmaceutically acceptable excipient is described. Such compressed core is useful for the preparation of pharmaceutical compositions containing a drug in which dissolution of the drug is favored in acidic environments. Also described are pharmaceutical compositions comprising such compressed core. | 11-29-2012 |
20120301542 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF - The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof. | 11-29-2012 |
20120308654 | ABUSE-PROOFED DOSAGE FORM - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 12-06-2012 |
20120315327 | ANTI-DIABETIC COMPOSITION CONTAINING A PLANT EXTRACT OF ENGLERINA LECARDII - The invention relates to a pharmaceutical antidiabetic composition containing, among the active ingredients thereof, a plant extract of | 12-13-2012 |
20130004570 | NUTRITIONAL SUPPLEMENT FOR USE UNDER PHYSIOLOGICALLY STRESSFUL CONDITIONS - In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 500 mg of vitamin C; about 400 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folic acid; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 75 mcg of biotin; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 10 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 400 mcg of lutein; about 125 mcg of lycopene; and at least one or more excipients. | 01-03-2013 |
20130004571 | Orally Effective Methylphenidate Extended Release Powder and Aqueous Suspension Product - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 01-03-2013 |
20130089604 | Solid Oral Dosage Form Containing An Enhancer - The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form. | 04-11-2013 |
20130095177 | METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD - The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form containing fingolimod and accordingly intermediates, granules and oral dosage forms obtainable by that method. | 04-18-2013 |
20130108693 | Dual Controlled Release Dosage Form | 05-02-2013 |
20130108694 | DRY BLEND FORMULATION OF TETRAHYDROBIOPTERIN | 05-02-2013 |
20130108695 | Dosage Form | 05-02-2013 |
20130115281 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION - A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form comprising a statin compound and at least one liquid fill phase comprising Omega-3 fatty acids. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. The solid phase, liquid phase or coatings may further comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, or therapeutic substances, functional excipients or combinations thereof. | 05-09-2013 |
20130115282 | POLYVALENT POLYMERIC MATRIX FOR MODIFIED RELEASE SOLID ORAL PREPARATIONS AND METHOD OF PREPARATION THEREOF - A polymeric matrix for oral administration with modified release and taste masking properties is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of active substance directly and individually covered with a release regulating membrane. Use of such a matrix to prepare various administration forms for oral use as well as the method of its preparation are also disclosed. | 05-09-2013 |
20130129819 | Pharmaceutical Formulations Containing An SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 05-23-2013 |
20130129820 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 05-23-2013 |
20130136792 | MULTI PHASE SOFT GEL CAPSULES, APPARATUS AND METHOD THEREOF - A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multiphase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof. | 05-30-2013 |
20130142871 | ORAL DOSAGE FORM OF DEFERASIROX - The invention relates to an oral dosage form containing deferasirox, binder, disintegrant and optionally wicking agent, wherein the introduction of the dosage form into water leads to a suspension wherein the suspended particles have an average particle size (D50) of 20 μm to 120 μm, and also to a method of producing it. | 06-06-2013 |
20130171253 | COMPOSITIONS FOR THE VAGINAL AND ORAL ADMINISTRATION OF LACTOBACILLUS AND USES THEREOF - The present invention relates to compositions for the oral and vaginal administration of human Lactobacilli and uses thereof for physiologic restoration of the vaginal flora, physiologic maintenance of | 07-04-2013 |
20130195973 | EXTENDED RELEASE PHARMACEUTICAL DOSAGE FORMS OF CARBIDOPA AND LEVODOPA AND PROCESS OF PREPARATION THEREOF - The present invention relates to an extended-release pharmaceutical dosage form of carbidopa and levodopa comprising (i) an immediate-release unit of carbidopa and levodopa; (ii) an extended-release unit of carbidopa and levodopa; and (iii) an immediate or extended-release unit of a carboxylate salt. The present invention further provides a process of preparation thereof. | 08-01-2013 |
20130202690 | ENCAPSULATED PICOPLATIN - The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about 10 microns. The picoplatin particles are dispersed within the powder of the formulation which includes a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate and an effective amount of up to about 5 wt % of a lubricant. | 08-08-2013 |
20130202691 | MODIFIED STARCH DERIVATIVE-BASED MATRIX FOR COLON TARGETING - A controlled-release oral pharmaceutical composition of at least an active agent, including: a) a lipophilic matrix consisting of lipophilic compounds and/or amphiphilic compounds; and b) an hydrophilic matrix, wherein the hydrophilic matrix includes at least an indigestible polysaccharide, the active ingredient being dispersed in the lipophilic and/or the hydrophilic matrix. | 08-08-2013 |
20130209553 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF PRAMIPEXOLE - The present invention discloses an extended release pharmaceutical composition of pramipexole or salts thereof comprising at least 40% w/w of hydrogenated castor oil, and one or more pharmaceutically acceptable excipients. | 08-15-2013 |
20130216617 | PHARMACEUTICAL COMPOSITIONS OF (R)-LANSOPRAZOLE - The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers. | 08-22-2013 |
20130216618 | SOFT CAPSULE BASED ON STARCH AND A METHOD AND DEVICE FOR THE PRODUCTION THEREOF - A method for producing starch soft capsules comprises the following steps: preparing a mixture comprising starch, plasticizer and water, wherein more than 50 weight percent of the starch is present in the form of particles of granular starch; shaping the mixture to form a film in a shaping process; solidifying the mixture by increasing the temperature of the mixture during and/or after the shaping process by more than 5° C.; and shaping the film to form a soft capsule. Soft capsules produced by this method have starch particles bonded to one another. A device for performing this method comprises a shaping device to enable shaping of the starch material to form a film, and a heating device to perform a heat treatment to destructure the starch during and/or after the shaping. It comprises a rotary die device. | 08-22-2013 |
20130230586 | Treatment of Tinnitus and Related Auditory Dysfunctions - The invention provides an extended-release dosage form of cyclobenzaprine for use in the treatment of tinnitus and related auditory dysfunctions by once-a-day oral administration, wherein the dosage form is a tablet or capsule comprising cyclobenzaprine as active agent in an amount from 10-80 mg, preferably from 10-60 mg. The active agent is associated with a polymer coating or matrix that comprises a water-insoluble polymer, the polymer coating or matrix providing the dosage form with an extended release of the active agent over at least 12 hours and preferably over at least 16 hours when the dosage form is administered to a patient. | 09-05-2013 |
20130236539 | METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 09-12-2013 |
20130243853 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS - Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof. | 09-19-2013 |
20130251791 | COMPOSITION COMPRISING A BENZIMIDAZOLE AND PROCESS FOR ITS MANUFACTURE - The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention. | 09-26-2013 |
20130251792 | ENCAPSULATION OF HEAT AND MOISTURE SENSITIVE SUBSTANCES - The present invention relates to a method for preparing a suspension for the encapsulation of heat and moisture sensitive substances in capsules, sachets, droplets and food compositions. It also relates to methods for encapsulating, to the encapsulated products and to methods for storing the encapsulated products. The invention is extremely suitable for the encapsulation of microbial cultures. Cultures encapsulated in capsules prepared according to the method of the invention, will stay stable for a long time. At 25 degrees C. they show a stability reduction of less than 1 log per month. | 09-26-2013 |
20130259931 | ORAL PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL AND PROCESS FOR THEIR PREPARATION - The present invention is directed to pharmaceutical compositions comprising nebivolol. More particularly, the present invention is directed to oral pharmaceutical compositions comprising nebivolol hydrochloride having a specific surface area of less than 22×10 | 10-03-2013 |
20130259932 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 10-03-2013 |
20130273153 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans - Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided. | 10-17-2013 |
20130280324 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN - The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations. | 10-24-2013 |
20130302416 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS - New substituted tricyclic compounds of formula (I) are described, wherein R1, R2, X, Y, Z are herein defined, having protein kinase inhibiting activity. The invention includes methods to prepare the compounds of formula (I), pharmaceutical compositions containing them, and their use in therapy, in particular for the treatment of diseases caused by and/or associated with dysregulated activity of protein kinase. | 11-14-2013 |
20130309298 | FORMULATIONS COMPRISING EXINE SHELLS - A formulation containing an active substance encapsulated within an exine shell of a naturally occurring spore, together with a protective additive which is also encapsulated within the exine shell. | 11-21-2013 |
20130309299 | THERAPEUTIC DELIVERY SYSTEM - Therapeutic delivery systems are provided which, in a first embodiment, contain a plurality of multiphase capsules in which first and second therapeutic agents are contained in separate phases within said multiphase capsules, and are disposed to deliver said first and therapeutic agents by at least two different delivery mechanisms. | 11-21-2013 |
20130337058 | Micronized Tanaproget and Compositions Containing Same - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 12-19-2013 |
20140010869 | FORMULATION AND MANUFACTURING PROCESS FOR CALCIUM ACETATE CAPSULES - The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule. | 01-09-2014 |
20140023703 | NANOCAPSULES WITH A POLYMER SHELL - The invention relates to a system for administering active ingredients, including nanocapsules comprising an oil, a cationic surfactant and a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic-polyethyleneglycol acid (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination of same and, optionally, an active ingredient, with the condition that when the polymer includes polyglutamic acid or polyglutamic-polyethyleneglycol acid (PGA-PEG) the active ingredient is not a didemnin or a tamandarin. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical compositions thereof and the use of same in medicine. | 01-23-2014 |
20140037722 | METHODS AND COMPOSITIONS OF CAMEL DERIVED PRODUCTS - The present invention provides a composition, a dairy product, and a method for treating a disorder in a subject. The composition includes (i) polymeric nanoparticles and (ii) camel derived glycosaminoglycans (GAG)s ionic complex encapsulated into the nanoparticles, at least one active ingredient encapsulated into the nanoparticles, or combinations thereof. The nanoparticles are lactoferrin nanoparticles including camel derived lactoferrin, casein nanoparticles including camel derived casein, or combinations thereof. The dairy product includes ice cream or frozen yogurt, wherein the ice cream or frozen yogurt includes the composition and is derived from camel milk or other species of milk. The method for treating a disorder in a subject includes administering a therapeutic dose of the composition to the subject. | 02-06-2014 |
20140050784 | PHARMACEUTICAL COMPOSITIONS OF MEMANTINE - The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations. | 02-20-2014 |
20140105973 | METHOD OF TREATING A DISEASE CONDITION SUSCEPTIBLE TO BACLOFEN THERAPY - The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients. | 04-17-2014 |
20140134242 | DELIVERY PARTICLE - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents that do not require or require a reduced amount of scavenger materials. Such encapsulated benefit agents, compositions comprising such encapsulated benefit agents are processed such that no or lower levels of scavenger materials are required. | 05-15-2014 |
20140141075 | 5-AMINOSALICYLIC ACID CAPSULE FORMULATION - A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed. | 05-22-2014 |
20140147497 | PEDIATRIC FORMULATION - The present invention is directed to pediatric formulation of (R)-N-[-1-(1-naphthyl)-ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine hydrochloride (hereinafter referred to as Cinacalcet HCl) and method of administering the same. | 05-29-2014 |
20140154311 | Enteric Soft Capsules - A gel mass is provided that is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating. | 06-05-2014 |
20140154312 | ORAL TARGETTED DRUG DELIVERY SYSTEM - The present invention discloses an “Improved Oral Targetted Drug Delivery System (O-TDDS)” particularly suited for delivery of drugs having activity against the diseases located in the colon e.g. colon cancer, ulcerative colitis, protozoal infections etc. The system comprises two elements or parts viz. microspheres (drug+natural polymers such as guar gum or xanthan gum) and probiotics. Both the elements are packed together in a single, pharmaceutically acceptable oral dosage form such as a capsule. The system offers distinct advantages of drug delivery without undesirable side-effects of diarrhea, nausea or vomiting commonly encountered in case of anti-cancer drugs such as 5-Fluorouracil. | 06-05-2014 |
20140154313 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration - The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a watersoluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours. | 06-05-2014 |
20140178467 | CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism. | 06-26-2014 |
20140186437 | ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS - The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats. | 07-03-2014 |
20140199386 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 07-17-2014 |
20140199387 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 07-17-2014 |
20140199388 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 07-17-2014 |
20140205659 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 07-24-2014 |
20140212484 | MULTILAYERED POLYELECTROLYTE-BASED CAPSULES FOR CELL ENCAPSULATION AND DELIVERY OF THERAPEUTIC COMPOSITIONS - The present invention provides novel, biocompatible matrices for cell encapsulation and transplantation. It further provides methods for delivering agents to encapsulated cells and to the local environment of a host system. The invention also provides methods for targeting and manipulating particular cells and/or proteins of the host system. In a composition aspect of the invention, a composition including a collection of capsules is provided. The capsules comprise an inner core, and the inner core is covered by an outer shell composed of a positive polyelectrolyte and a negative polyelectrolyte. The inner core of the capsules contains at least one cell. | 07-31-2014 |
20140220119 | Capsules Containing High Doses of Levodopa for Pulmonary Use - The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide. | 08-07-2014 |
20140220120 | CRYSTAL ENTECAVIR, CRYSTAL ENTECAVIR FORMULATION AND METHODS FOR THE PREPARATION THEREOF - The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity. | 08-07-2014 |
20140234409 | NICOTINAMIDE COMPOSITIONS AND THE THERAPEUTIC USE THEREOF - The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invention concerns the treatment and/or prevention of ADHD, ADD and autism spectrum disorders. The present inventors have developed a method for prophylaxis or treatment of such symptoms and/or pathologies associated with a deficiency in essential amino acid absorption and/or metabolism, which method, stated generally, relies on the administration of nicotinamide, typically in a long-acting formulation so as to overcome the deficiencies of existing formulations, which have proven unsuitable for effective treatment. | 08-21-2014 |
20140234410 | COMBINATION PRODUCTS - A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active ingredient, and at least some of the minicapsules containing a corticosteroid as another active ingredient. | 08-21-2014 |
20140242159 | Method for Preparing a Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients - A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need. | 08-28-2014 |
20140242160 | CALCIUM SUPPLEMENT - An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and an extended release system that maintains the calcium level in the animal's bloodstream at a substantially beneficial level for a defined period of time. | 08-28-2014 |
20140248341 | ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS - Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof. | 09-04-2014 |
20140255479 | Pharmaceuticals for Oral Delivery - The present invention provides pharmaceutical compositions suitable for oral and methods of treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance bioavailability of at least one compound classified as BCS Class II, BCS Class III or BCS Class IV. | 09-11-2014 |
20140255480 | PHARMACEUTICAL FORMULATION OF NANONIZED FENOFIBRATE - The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof. | 09-11-2014 |
20140271834 | Doxycycline Formulations, and Methods of Treating Rosacea - The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean C | 09-18-2014 |
20140271835 | ABUSE RESISTANT CAPSULE - The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics. | 09-18-2014 |
20140271836 | MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION - The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies. | 09-18-2014 |
20140271837 | PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM - A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin and a plasticizer; and (b) a fill that includes at least one active ingredient, polyethylene glycol, polyacrylic acid, a neutralizing agent, and water. The neutralizing agent is a primary amine or a secondary amine, and is present in an amount necessary to provide a pharmaceutical soft gelatin capsule dosage form having stable dissolution after storage. | 09-18-2014 |
20140271838 | PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM WITH MODIFIED GUAR GUM - A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage. | 09-18-2014 |
20140271839 | EXTENDED-RELEASE TOPIRAMATE CAPSULES - An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s). | 09-18-2014 |
20140287034 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 09-25-2014 |
20140287035 | PANCREATIC ENZYME COMPOSITIONS AND METHODS FOR TREATING PANCREATITIS AND PANCREATIC INSUFFICIENCY - Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies. | 09-25-2014 |
20140294948 | COMPOSITION AS AUXILIARY MEANS FOR ORAL MEDICATION - The invention relates in one aspect to a composition, specifically a jelly, the use of which composition as an auxiliary means is to ease the taking of oral medication in solid form, which composition comprises iota-carrageenan as a jellifying agent and citric acid as a salivating agent, characterized in that the composition further comprises maltodextrin. In another aspect, the composition comprises a calcium sequestrant for adjusting Ca-ion activity of the composition. In one embodiment, the composition comprises iota-carrageenan in 0.7-1.0% in mass, citric acid in 0.06-0.07% in mass, maltodextrin in 1.5% in mass, all relative to the total mass of the composition, and an amount of a calcium sequestrant such that the Ca-ion activity of the composition is between 20 ppm and 80 ppm. | 10-02-2014 |
20140302131 | ORAL FORMULATIONS CONTAINING HYALURONIC ACID FOR SUSTAINED DRUG RELEASE - The present invention discloses a tablet or a capsule for oral administration comprising 0.5-0% (w/w) hyaluronic acid or a salt thereof, an active pharmaceutical ingredient (API), and a coating. | 10-09-2014 |
20140302132 | PHARMACEUTICAL COMPOSITION COMPRISING NANOCRYSTALS - The present invention relates to processes for the manufacture of suspensions comprising one or more water soluble or water insoluble pharmaceutical or nutraceutical active ingredients with a particle size in the range of from 0.01 to 10 micron. More specifically, suspensions prepared by this process can be used to formulate pharmaceutical compositions, especially in liquid fill capsules. | 10-09-2014 |
20140322313 | PHARMACEUTICAL COMPOSITIONS OF IBUPROFEN AND AN H2 RECEPTOR ANTAGONIST - Pharmaceutical compositions of a H | 10-30-2014 |
20140328908 | CONTROLLED-RELEASE FORMULATION - The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 μg/kg body weight/minute and 20 μg/kg body weight/minute. | 11-06-2014 |
20140335169 | Peptide Pharmaceutical for Oral Delivery - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds. | 11-13-2014 |
20140335170 | Reduced Mass Metformin Formulations - The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules. | 11-13-2014 |
20140335171 | Stable Formulations of Antiplatelet Agents, Omega-3 Fatty Acids and Amylose In Soft Gelatin Capsules - The invention discloses stable formulations of acetylsalicylic acid or salts thereof, omega-3 fatty acids and amylose in soft gelatin capsules. | 11-13-2014 |
20140341985 | METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 11-20-2014 |
20140341986 | Biguanide Compositions and Methods of Treating Metabolic Disorders - Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 11-20-2014 |
20140363503 | CHEWABLE SOFT CAPSULES - A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided. | 12-11-2014 |
20140370082 | CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS - The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA | 12-18-2014 |
20140370083 | 5-AMINOSALICYLIC ACID CAPSULE FORMULATION - A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed. | 12-18-2014 |
20140377343 | FORMULATIONS OF FLURBIPROFEN AND DIACEREIN - The present invention relates to a pharmaceutical formulation, characterized by comprising flurbiprofen or a pharmaceutically acceptable salt of flurbiprofen, diacerein or a pharmaceutically acceptable salt of diacerein, as well as at least one or a properly-proportioned mixture of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or polyvinyl alcohol-polyethylene glycol copolymer. | 12-25-2014 |
20140377344 | PROTEASE INHIBITOR-CONTAINING COMPOSITIONS, COMPOSITIONS COMPRISING SAME, AND METHODS FOR PRODUCING AND USING SAME - Provided herein are methods and compositions for oral administration of therapeutic proteins, improved protease inhibitor preparations, methods for producing same, and compositions comprising same. | 12-25-2014 |
20150010621 | SUSTAINED RELEASE SOLID DOSAGE PREPARATIONS - A sustained release solid dosage preparation is provided comprising an active ingredient admixed with an excipient. At least part of the excipient consists of glucomannan microparticles having an average particle size less than 50 μm. The glucomannan microparticles forms, when absorbing water, a hydrogel matrix for the active ingredient capable releasing the active ingredient almost entirely up about 6 hours. | 01-08-2015 |
20150010622 | CAPSULE FORMULATION COMPRISING FEXOFENADINE - The present invention relates to a composition for use as a capsule fill comprising (a) fexofenadine hydrohalide; (b) alkali hydroxide, wherein the molar ratio of the alkali hydroxide to fexofenadine is greater than 1.5:1; (c) a solvent, and optionally a solubilizer. This composition is a stable solution, and comprises a sufficiently high concentration of fexofenadine to be useful for manufacture of capsules comprising a pharmaceutically efficacious amount of the fexofenadine for treatment of the symptoms of allergies, hay fever, or urticarial. Further, the present invention relates to a capsule comprising such a fill. | 01-08-2015 |
20150010623 | CONTROLLED RELEASE PREPARATIONS - Controlled release preparations and soft capsules are provided. Also provided are emulsions and suspensions, including compositions and methods of manufacturing controlled release soft capsules, where the fill contains a suspension and/or an emulsion. | 01-08-2015 |
20150024042 | PHASED DOSING OF CLOPIDOGREL - The present invention provides for novel formulations of clopidogrel to provide for phased/spaced release for use as improved antiplatelet therapies in stroke and cardiovascular indications. | 01-22-2015 |
20150030674 | COMPOSITION FOR POLYUNSATURATED FATTY ACIDS ENCAPSULATION AND PROCESS OF PREPARATION - The application relates to an encapsulated composition comprising from about 40% (w/w) to about 90% (w/w) of the encapsulating composition comprising from about 14% (w/w) to about 90% (w/w) whey protein isolate with a special ionic profile, from about 5% (w/w) to about 80% (w/w) of one or more low molecular weight carbohydrates, and from about 3% (w/w) to about 15% (w/w) antioxidant; and encapsulating from about 10% (w/w) to about 60% (w/w) polyunsaturated fatty acids. | 01-29-2015 |
20150044282 | ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE OXYCODONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 02-12-2015 |
20150044283 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI - Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by | 02-12-2015 |
20150064245 | Abuse Resistant Forms of Immediate Release Hydromorphone, Method of Use and Method of Making - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-05-2015 |
20150064246 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE OXYMORPHONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-05-2015 |
20150071994 | GASTROINTESTINAL SITE-SPECIFIC ORAL VACCINATION FORUMULATIONS ACTIVE ON THE ILEUM AND APPENDIX - The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided. | 03-12-2015 |
20150071995 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE HYDROCODONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-12-2015 |
20150071996 | FORMULATION AND MANUFACTURING PROCESS FOR CALCIUM ACETATE CAPSULES - The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule. | 03-12-2015 |
20150079163 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE - The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions. | 03-19-2015 |
20150086623 | CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION INCLUDING TAMSULOSIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND ORAL FORMULATION INCLUDING THE SAME - A controlled-release pharmaceutical composition including first and second groups of microparticles, each of the microparticles including a core including tamsulosin or pharmaceutically acceptable salts thereof, a controlled-release polymer coating layer formed on the core, and an enteric polymer outer layer formed on the controlled-release polymer coating layer, wherein the average thickness of the controlled-release polymer coating layer is different in each of the first and second groups of microparticles, and an oral formulation including the same, are provided. This pharmaceutical composition can easily control the extent of release of an active ingredient depending on changes in pH in the intestinal tract and the release pattern of the active ingredient in the small intestine, thus preventing the active ingredient from being rapidly transferred into the blood to thereby minimize side-effects, and maintaining the effective blood concentration of the active ingredient for a predetermined period of time. Furthermore, this composition can shield the bitter taste of the active ingredient even when exposed to the inside of the mouth, thus increasing the therapeutic effects for patients upon oral administration. | 03-26-2015 |
20150098991 | ORAL ADMINISTRATION - The present invention is within the field of administration of biopharmaceuticals. More specifically, the invention provides for oral administration of a compound comprising a moiety which confers a desired therapeutic activity; and a polypeptide moiety which binds to albumin. | 04-09-2015 |
20150098992 | COMPOSITE FORMULATION COMPRISING MULTI-UNIT SPHEROIDAL TABLET (MUST) ENCAPSULATED IN HARD CAPSULE AND METHOD FOR PREPARING SAME - Provided is a composite formulation comprising multi-unit spheroidal tablets (MUSTs) encapsulated in a hard capsule and a method for preparing same. The inventive hard capsule composite formulation can effectively charge the MUSTs in the limited space of the capsule, which allows charging a high dose of different pharmaceutically active ingredients in a capsule with a relatively small size, to thereby increase the productivity and render it readily administered to patients. Also, the capsule has a good dissolution rate because the pharmaceutically active ingredients contained in the capsule are separated from one another; therefore, the dissolution rates of the ingredients are less affected by one another. It may also be possible to maximize the therapeutic effects of the pharmaceutically active ingredients since the composite formulation has good stability. | 04-09-2015 |
20150104504 | COMPOSITIONS OF STATINS AND OMEGA-3 FATTY ACIDS - The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms. | 04-16-2015 |
20150110867 | TECHNIQUES FOR RELEASE OF MATERIAL INTO AN ENVIRONMENT - Systems and methods for releasing a material into an environment. The material may be encapsulated in a receptacle or otherwise packaged for movement into the environment. The receptacle with the material inside is introduced into the environment. A triggering causes release of the material from the receptacle into the environment. | 04-23-2015 |
20150110868 | METHODS FOR TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate. | 04-23-2015 |
20150118294 | Triggerable Compositions For Two-Stage, Controlled Release of Proactive Chemistry - A triggerable composition for two-stage, controlled release of a functional active chemical includes a trigonelline ester of a functional active with at least one hydroxyl group configured to release the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the trigonelline ester including a functional active, the encapsulation material triggerable to release the trigonelline ester upon the occurrence of an environmental stimulus. In other aspects, a viscous liquid or an absorbent article includes a triggerable composition for two-stage, controlled release of a functional active chemical, the composition including a trigonelline ester of a functional active with at least one hydroxyl group configured to release the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the trigonelline ester including a functional active. | 04-30-2015 |
20150118295 | Immediate Release Abuse-Deterrent Granulated Dosage Forms - Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse. | 04-30-2015 |
20150118296 | CONTROLLED RELEASE BUDESONIDE COMPOSITIONS - The present invention relates to controlled release pharmaceutical compositions comprising budesonide. The invention also relates to processes for the preparation of such compositions and using those compositions in the treatment of Inflammatory Bowel Disease and Irritable Bowel Syndrome including mild to moderate ulcerative colitis. | 04-30-2015 |
20150132374 | FORMULATIONS - A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon. | 05-14-2015 |
20150132375 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 05-14-2015 |
20150132376 | MULTI-COMPARTMENTED CONTAINER - The invention provides a multi-compartmented container suitable for the delivery of pharmaceuticals, medicines, vitamins, and the like. | 05-14-2015 |
20150140084 | ACID RESISTANT BANDING SOLUTION FOR TWO PIECE HARD CAPSULES - The present disclosure relates to acid resistant banding solutions for two piece hard capsules, and methods of making the same. The present disclosure also relates, in part, to a method for banding such capsules which provides an acid resistant seal between the capsule parts and achieves an increased acid resistance in vitro. The instant disclosure further relates to a capsule sealing solution formula that comprises shellac ink or shellac ink vehicle component. | 05-21-2015 |
20150140085 | FORMULATIONS COMPRISING IBRUTINIB - Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases. | 05-21-2015 |
20150140086 | Tamper Resistant Co-Extruded Dosage Form Containing an Active Agent and an Adverse Agent and Process of Making Same - The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms arc useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. | 05-21-2015 |
20150140087 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists - Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome. | 05-21-2015 |
20150147391 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 05-28-2015 |
20150290140 | COMPOSITIONS COMPRISING MICROPARTICLES AND PROBIOTICS TO DELIVER A SYNERGISTIC IMMUNE EFFECT - Microparticulate compositions and nutritional compositions containing the microparticulate compositions are disclosed herein. In a general embodiment, the microparticulate compositions include one or more probiotics and have a size ranging from about micron to about 20 microns. The microparticulate compositions can be added to any suitable nutritional composition. | 10-15-2015 |
20150297530 | FIXED DOSE COMBINATION THERAPY OF PARKINSON'S DISEASE - A pharmaceutical composition for use in treatment of Parkinson's disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline, wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline, and the dose of pramipexole is lower than or equal to the dose of rasagiline. | 10-22-2015 |
20150313847 | Compressed Tablets - The present invention pertains to a method of producing a compressed tablet in a rotary tablet press. The method including the steps of adding a first powdered portion of tablet base material into a punch die of a rotary tablet press, pressing the first tablet base material by means of an upper and a lower punch to obtain a first pressed material, inserting an object at the upper face of the first pressed material and fixing the object in a central cavity of the first pressed material, adding a second powdered portion of tablet base material into the punch die of the rotary tablet press, and pressing the first and second tablet base material around the object to enclose the object from the surface of the tablet. The object is based on a material different from the first and/or the second powdered portion of tablet base material. | 11-05-2015 |
20150313849 | Methods of Treatment of Attention Deficit Hyperactivity Disorder - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours. | 11-05-2015 |
20150313968 | ORAL DELIVERY FOR HEMOGLOBIN BASED OXYGEN CARRIERS - A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility of hemoglobin, intestinal absorption enhancers are added in each of the HBOC formulations. Protective layers ensure delivery of an intact hemoglobin structure in intestinal tract without degradation in the stomach. The HBOC formulations may be used for preventive or immediate treatment of high altitude syndrome (HAS) or for treatment of hypoxic conditions including blood loss, anemia, hypoxic cancerous tissue, and other oxygen-deprivation disorders. In addition to delivering oxygen, the heme group of hemoglobin from HBOC formulations can provide heme iron to the human body to aid in the production of more red blood cells. | 11-05-2015 |
20150320689 | ABUSE DETERRENT IMMEDIATE RELEASE COATED RESERVOIR SOLID DOSAGE FORM - An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered. | 11-12-2015 |
20150320690 | TAMPER RESISTANT IMMEDIATE RELEASE CAPSULE FORMULATION COMPRISING TAPENTADOL - The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe. | 11-12-2015 |
20150328165 | PHARMACEUTICALLY ACCEPTABLE DOSAGE FORM COMPRISING RELEASE OF MULTIPLE DRUGS FROM SINGLE ORAL DOSAGE FORM - Present invention relates to a pharmaceutically acceptable dosage form covering multiple drug in one capsule wherein one of these drugs is tetracycline. In the present invention current dosage form tetracycline is in tablet form filled in the capsule. Additionally this dosage may also comprise multiple release of drug. | 11-19-2015 |
20150328168 | ORAL FORM, COMPRISING IMMEDIATE-RELEASE COATED PARTICLES OF AT LEAST ONE ACTIVE COMPOUND THAT ARE GRINDING-RESISTANT - An oral dosage form for the immediate release of at least one active compound, comprising coated particles consisting of a non-monocrystalline core containing said active compound and coated with at least one coating layer, said coating layer comprising (A) at least 15% by weight of water-insoluble polymer and (B) at least 40% by weight of polymer soluble in a 0.1N hydrochloric acid solution, the weight ratio polymer B/polymer A being comprised between 85/15 and 50/50, said coating layer representing at least 30% by weight of the total weight of said coated particles. | 11-19-2015 |
20150328215 | STABLE AMORPHOUS RALTEGRAVIR POTASSIUM PREMIX AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to a stable amorphous Raltegravir potassium premix, method of making and pharmaceutical composition thereof. | 11-19-2015 |
20150328316 | Magnesium hydroxide carbonate as excipient in pharmaceutical preparations having improved release of active ingredient - The present invention relates to pharmaceutical formulations of active ingredients which have low solubility in aqueous solutions, having improved release of active ingredient, and to a process for the preparation thereof. In particular, these are pharmaceutical preparations in which magnesium hydroxide carbonate serves as excipient. | 11-19-2015 |
20150329622 | ANTI-BAG3 ANTIBODIES FOR THERAPEUTIC USE - The present invention relates to the use of BAGS antibodies as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic and/or degenerative nature. | 11-19-2015 |
20150335586 | CAPSULE DISPENSING CONTAINER - A package for delivering a single-dose product includes a softgel capsule which is comprised of at least one gelling agent selected from protein-based gelling agents and polysaccharide-based gelling agents. The capsule shell includes one or more areas of reduced thickness that are preferentially ruptured by exertion of a compressive force on the softgel capsule to create an opening in the capsule shell through which the fill composition can be delivered by spraying or squeezing. A method for manufacturing the softgel capsule having one or more areas of reduced shell thickness is also described. | 11-26-2015 |
20150335587 | CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY - The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide. | 11-26-2015 |
20150335588 | Oral Dosage Forms of Bendamustine - In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide. | 11-26-2015 |
20150335668 | METHOD FOR CANCER THERAPY - The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, | 11-26-2015 |
20150335753 | SUPERSATURATED STABILIZED NANOPARTICLES FOR POORLY SOLUBLE DRUGS - A pharmaceutical composition and method of producing supersaturated stabilized nanoparticles of poorly soluble drugs having average sizes less than 1 μm, or less than 800 nm, or less than 500 nm, comprising at least one pharmaceutically active ingredient, a hydrophilic polymer, a water-soluble surfactant, and subsequently stabilized by ionic polymers. | 11-26-2015 |
20150343068 | GLYPISOME AS AN ENHANCER OF ANGIOGENIC GROWTH FACTOR ACTIVITY - Disclosed herein are proteovesicles, referred to herein as a “glypisomes”, that comprise a recombinant glypican polypeptide embedded in a lipid vesicle. Also disclosed is the use of these glypisomes to enhance the activity of growth factors. | 12-03-2015 |
20150352054 | Enteric Soft Capsules - A gel mass is provided that is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating. | 12-10-2015 |
20150359737 | SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION - According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy. | 12-17-2015 |
20150359795 | HIGH DRUG LOAD PHARMACEUTICAL COMPOSITIONS WITH CONTROLLABLE RELEASE RATE AND PRODUCTION METHODS THEREOF - High drug load pharmaceutical compositions and production methods thereof are provided. The pharmaceutical composition includes at least one viscous active pharmaceutical ingredient or a pharmaceutically acceptable salts thereof. The at least one viscous active pharmaceutical ingredient accounts for at least 60% by weight of the total solid weight of the pharmaceutical composition. The saturated solution of the at least one viscous active pharmaceutical ingredient has a viscosity of at least 20 centipoises at 25° C. Alternatively, the aqueous solution of the at least one viscous active pharmaceutical ingredient with a concentration lower than 55 wt % has at least a viscosity of at least 10 centipoises at 25° C. | 12-17-2015 |
20150366811 | PHARMACEUTICAL PRODUCTS - Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles. | 12-24-2015 |
20150366813 | LIQUID-FILLED IMMEDIATE RELEASE SOFT GELATIN CAPSULES - Described herein are oral pharmaceutical compositions comprising labile, air-, moisture-, or heat-sensitive active pharmaceutical ingredients and methods for making the same. In particular, immediate release capsules comprising non-aqueous fills comprising moisture-sensitive active pharmaceutical ingredients are described. | 12-24-2015 |
20150366861 | PHARMACEUTICAL FORMULATION CONTAINING IRRITANT - Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering. | 12-24-2015 |
20150374628 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 12-31-2015 |
20160000712 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 01-07-2016 |
20160000722 | DOSAGE FORM FOR CINEOLE - The invention relates to a dosage form containing cineole for peroral application in capsule form, wherein the dosage form containing cineole is designed as a capsule-in-capsule system, wherein the capsule-in-capsule system has an outer capsule (outside capsule) having an outer capsule shell and a plurality of inner capsules (inside capsules) located in the outer capsule, wherein the inner capsules are completely enclosed by the capsule shell of the outer capsule and the inner capsules are designed as microcapsules, which each contain the active ingredient 1,8-cineole. The invention further relates to the production and use of said dosage form containing cineole. | 01-07-2016 |
20160008290 | ORAL DELIVERY OF PROTEINS AND PEPTIDES | 01-14-2016 |
20160008371 | FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA | 01-14-2016 |
20160008474 | PHARMACEUTICAL FORMULATION CONTAINING GLYCOSAMINOGLYCAN | 01-14-2016 |
20160009767 | ORAL ADMINISTRATION | 01-14-2016 |
20160015647 | BISMUTH LIQUID FILLED HARD CAPSULES - The present disclosure relates to a new, stable, oil based liquid suspension filled hard capsule dosage form for bismuth salts such as bismuth subsalicylate, a process for its manufacture, methods to deliver bismuth salts to humans or animals via stable hard capsules, and improved methods of treating gastrointestinal disorders with such dosage forms. | 01-21-2016 |
20160015651 | HARD CAPSULE FORMULATION - A problem of the present disclosure is, in one embodiment, to create a hard capsule formulation that includes a pharmaceutical agent or the like whose components deteriorate upon contact with an acid, in which the pharmaceutical agent or the like does not deteriorate due to gastric acid penetrating into the outer shell of the hard capsule. A hard capsule formulation comprising a hard capsule with acid resistance, in which the hard capsule is not treated with enteric coating, and the hard capsule formulation comprises an agent to inhibit invasion of gastric fluid and a pharmaceutical agent in the hard capsule. | 01-21-2016 |
20160015733 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS - Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided. | 01-21-2016 |
20160022597 | L-Menthol Dosage Forms Having A Proteinaceous Coating For Enhanced Storage Stability - A storage stable L-menthol composition including a tablet, caplet, capsule, or sachet dosage form has therein a core containing crystalline L-menthol and at least one pharmaceutical excipient. A proteinaceous coating of a continuous film of proteinaceous material is over the core. The film is effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days. The dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder. | 01-28-2016 |
20160030289 | MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION - The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies. | 02-04-2016 |
20160030399 | METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 02-04-2016 |
20160030499 | Adaptogenic Compositions And Method For Production Thereof - A composition comprising a standardized amount of a schisandrin compound and methods for production thereof for use in reducing stress, increasing blood antioxidant level, reducing lipid peroxidation and/or improving symptoms of depression in subjects in need thereof. | 02-04-2016 |
20160038411 | PULSATILE GASTRIC RETENTIVE DOSAGE FORMS - Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of the dosage form. The dosage forms find particular use in administration of acid-labile active agents such as proton pump inhibitors, and in treating gastric acid secretion such as gastro-esophageal reflux disease (GERD) and nocturnal acid breakthrough (NAB). | 02-11-2016 |
20160038426 | EXTENDED-RELEASE TOPIRAMATE CAPSULES - An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s). | 02-11-2016 |
20160038431 | TIMED, PULSATILE RELEASE SYSTEMS - A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmocokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications. | 02-11-2016 |
20160038479 | Compositions with Thixotropy and Enhanced Dissolution Reproducibility and Stability - The present disclosure provides extended release compositions including, formulations that comprise such compositions, which exhibit desirable dissolution of an active agent while maintaining its physical stability in a dosage form including, for example, providing reduced sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions and formulations are also provided. | 02-11-2016 |
20160038547 | LACTOBACILLUS PLANTARUM CAPSULE FOR POULTRY AND USE THEREOF - The present invention relates to a | 02-11-2016 |
20160038592 | Compositions with a Rheological Modifier to Reduce Dissolution Variability - The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions are also provided. | 02-11-2016 |
20160045442 | STABLE PHARMACEUTICAL COMPOSITIONS OF MESALAMINE - The present invention relates to stable pharmaceutical compositions of mesalamine. The composition of the invention is a capsule dosage form filled with a tablet. The invention also relates to process for preparing such compositions. The invention specifically relates to a composition of mesalamine wherein the composition is devoid of any reducing sugar or sugar alcohol. | 02-18-2016 |
20160045444 | COMPOSITE FORMULATION COMPRISING A FILM COATING LAYER CONTAINING ROSUVASTATIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided is a composite formulation comprising: (i) a core including a first pharmacological component; and (ii) a film coating layer formed on a surface of the core, which contains rosuvastatin or a pharmaceutically acceptable salt thereof as a second pharmacological component and a polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol as a coating material. In the composite formulation of the present invention, tension and fluidity of the film coating layer are excellent, and thus breakage and a defective ratio are low. Accordingly, a composite agent containing rosuvastatin effective to relieve and treat a hyperlipemia symptom, or its pharmaceutically acceptable salt can be provided with high efficiency, and is present in a composite formulation form, and thus compliance of a patient can be improved. | 02-18-2016 |
20160045503 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS - Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases. | 02-18-2016 |
20160045523 | PHARMACEUTICAL FORMULATION COMPRISING PHOSPHATIDYLCHOLINE FOR THE TREATMENT OF ULCERATIVE COLITIS - A pharmaceutical formulation, comprising a phosphatidylcholine product of formula (I), wherein R | 02-18-2016 |
20160046635 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME - The present invention includes pyrimido[5,4-d]pyrimidines that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound of the invention. | 02-18-2016 |
20160051472 | PANCREATIC ENZYME COMPOSITIONS AND METHODS FOR TREATING PANCREATITIS AND PANCREATIC INSUFFICIENCY - Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies. | 02-25-2016 |
20160051480 | COMPOSITIONS AND METHODS FOR CANNABINOID COATINGS FOR USE IN DRUG DELIVERY - The present invention relates to coatings and methods for the administration of cannabinoids to a patient, and in a specific embodiment, the coatings and methods may utilize or include cannabinoids, and one or more active pharmaceutical ingredients, wherein said coating is configured for oral delivery through a capsule or tablet. | 02-25-2016 |
20160054218 | INTRALUMINAL PRESSURE DETECTION FOR DIVERTICULAR DISEASE - A pressure detection tablet is disclosed. The tablet is a capsule including a dye encapsulated within an inner coating, in which the inner coating is configured to rupture at a pressure equal to or greater than a pressure threshold. The tablet further includes an outer coating surrounding the capsule, in which the outer coating is configured to provide delivery of the capsule to a targeted site. The dye may be a non-metabolized, water soluble dye, such that a ruptured capsule releases the dye which can be visually detected in the urine. In some embodiments, the disclosure provides a method of making the tablet, using the tablet to detect peak pressure in the colon and reducing the risk of developing a colonic disorder. | 02-25-2016 |
20160058716 | PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 03-03-2016 |
20160058809 | Additional Artemisinin and Berberine Compositions and Methods of Making - An Alternative ACT composition consisting of natural botanical active ingredients, all of which are GRAS (generally regarded as safe by the FDA). The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives, berberine, capsaicin, and papaya extract. The four active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for the treatment and prevention of chikungunya. | 03-03-2016 |
20160067199 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 03-10-2016 |
20160074333 | Pharmaceutical compositions of tamsulosin or salts thereof - The present invention relates to pharmaceutical compositions of tamsulosin or salts thereof. In particular, the invention relates to pharmaceutical compositions comprising a core of tamsulosin or salts, hydrates thereof and at least one specialized coating over the core. Such compositions of tamsulosin may exhibit desired release kinetics with excellent storage stability and particularly, levels of degradants in the formulation during storage can be effectively controlled. The invention also includes a process of preparing such compositions and additionally combination with other pharmaceutical ingredient. | 03-17-2016 |
20160074406 | DRY BLEND FORMULATION OF TETRAHYDROBIOPTERIN - Dry blend powder formulations comprising a pharmaceutical formulation containing tetrahydrobiopterin, and methods of making and using the same, are disclosed herein. | 03-17-2016 |
20160089438 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 03-31-2016 |
20160101048 | +L-CARNOSINE ZINC FORMULATIONS AND METHODS OF USE - Various formulations of L-carnosine zinc (L-CAZ), and methods of using and administering such formulations to patients suffering from various diseases, disorders, or conditions are disclosed. In particular, low average particle size L-carnosine zinc is employed in various pharmaceutical compositions, including aqueous matrices and hydrogels. | 04-14-2016 |
20160106681 | CONTROLLED RELEASE OF VEGETARIAN PORE-SEALING CAPSULE IN STOMACH, DUODENUM, JEJUNUM, ILEUM AND COLON - A vegetarian pore-sealing capsule is provided. The pore-sealing capsule may release active substances in a gastrointestinal tract, including stomach, duodenum, jejunum, ileum and colon, under control. The pore-sealing capsule includes a capsule shell having one or more pores and a pore-sealing material for sealing at least one of the pores. When the pore-sealing capsule is located at a destination inside the gastrointestinal tract, the pore-sealing material will leave the pores. | 04-21-2016 |
20160106682 | Enteric Soft Capsules - A gel mass is provided that is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating. | 04-21-2016 |
20160106699 | Oral pharmaceutical composition containing combination of PPARa and a HMG-CoA reductase inhibitor - Oral pharmaceutical composition containing, in the same pharmaceutical form, effective amounts of a HMG-CoA reductase inhibitor derivative and of PPARα, especially fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissolution and/or bioavailability of the drugs from the said composition. | 04-21-2016 |
20160106763 | ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - The present invention relates to a pharmaceutical composition which includes a HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid in a manner to minimize interaction of acetylsalicylic acid with the statin, for use in the prevention or treatment of cardiovascular diseases. | 04-21-2016 |
20160106789 | Inhibition of Neurodegenerative Disease by Grape Seed Extract, Green Tea Extract and Probiotic Bacteria - A composition is provided comprising extracts of at least grape seeds (GSE) and green tea. The extracts are preferably polyphenolic and preferably comprise probiotic bacteria. The use of extracts from green tea and grape seeds for the manufacture of a medicament against a neurodegenerative disease is also disclosed. | 04-21-2016 |
20160106814 | Novel Oral Pharmaceutical Composition for Treatment of Diabetes - The invention provides improved solid oral pharmaceutical compositions comprising an insulin peptide or GLP-1 peptide and methods of producing such. | 04-21-2016 |
20160106841 | SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL AGENTS - Liquid and semi-solid pharmaceutical compositions, which can be administered in liquid form or can be used for preparing capsules, are described herein. The composition comprises the salt of one ore more active agents, polyethylene glycol, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of active agent, and water. The pH of the composition is adjusted within the range of 2.5-7.5. The de-ionizing agent causes partial de-ionization (neutralization) of the salt of the active agent resulting in enhanced bioavailability of salts of weakly acidic, basic or amphoteric active agents as well as lesser amounts of polyethylene glycol (PEG) esters. | 04-21-2016 |
20160120810 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 05-05-2016 |
20160120819 | METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER - There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described. | 05-05-2016 |
20160120859 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR - The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof. | 05-05-2016 |
20160120885 | FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA - Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (COX-2 inhibitor). Said methods comprise basing COX-2 inhibitor dose on each patient's pharmacokinetic response to said COX-2 inhibitor. | 05-05-2016 |
20160136101 | GASTRO-RESISTANT SOFT SHELL CAPSULE AND PROCESS FOR ITS MANUFACTURE - The invention relates to gastro-resistant soft shell capsules having a capsule shell comprising high acyl gellan gum, at least one starch and at least one plasticizer, wherein the capsules fulfil pharmacopoeial disintegration tests characterizing the capsules as gastro-resistant dosage forms. The invention further relates to a method for manufacturing such gastro-resistant soft shell capsules. | 05-19-2016 |
20160143856 | CAPSULE DOSAGE FORM OF METOPROLOL SUCCINATE - The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation. | 05-26-2016 |
20160143989 | COMPOSITION COMPRISING OIL DROPS - A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are free of active principle. The oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant. | 05-26-2016 |
20160144030 | TECHNIQUES FOR RELEASE OF MATERIAL INTO AN ENVIRONMENT - Systems and methods for releasing a material into an environment. The material may be encapsulated in a receptacle or otherwise packaged for movement into the environment. The receptacle with the material inside is introduced into the environment. A triggering causes release of the material from the receptacle into the environment. | 05-26-2016 |
20160151310 | ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF | 06-02-2016 |
20160151332 | 4-Methylpyrazole Formulations | 06-02-2016 |
20160151355 | Pharmaceutical Formulation Containing Gelling Agent | 06-02-2016 |
20160158159 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 06-09-2016 |
20160175248 | Omega-3 Fatty Acid Ester Compositions Unitary Pharmaceutical Dosage Forms | 06-23-2016 |
20160184232 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans - Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided. | 06-30-2016 |
20160193345 | Oral Drug Delivery System | 07-07-2016 |
20160250170 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | 09-01-2016 |
20160250207 | Treating Pain In Patients With Hepatic Impairment | 09-01-2016 |
20160374948 | ABUSE RESISTANT CAPSULE - The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics. | 12-29-2016 |
20160374965 | TAMPER RESISTANT IMMEDIATE RELEASE CAPSULE FORMULATION COMPRISING TAPENTADOL - The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe. | 12-29-2016 |
20160375141 | ORAL DELIVERY SYSTEM FOR HEMOGLOBIN BASED OXYGEN CARRIERS - A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility of hemoglobin, intestinal absorption enhancers are added in each of the HBOC formulations. Protective layers ensure delivery of an intact hemoglobin structure in intestinal tract without degradation in the stomach. The HBOC formulations may be used for preventive or immediate treatment of high altitude syndrome (HAS) or for treatment of hypoxic conditions including blood loss, anemia, hypoxic cancerous tissue, and other oxygen-deprivation disorders. In addition to delivering oxygen, the heme group of hemoglobin from HBOC formulations can provide heme iron to the human body to aid in the production of more red blood cells. The presently claimed invention provides improved hemoglobin formulations for forming nanoparticles with improved properties via polyelectrolyte complexation and for lyophilization to form mixture powder or particles with improved properties. | 12-29-2016 |
20170231927 | PHARMACEUTICAL COMPOSITIONS OF MEMANTINE | 08-17-2017 |
20170231942 | FUMARATE ESTER DOSAGE FORMS | 08-17-2017 |
20190142756 | DRUG FORMULATIONS | 05-16-2019 |